Drugs with expired main patents
1. Abilify patent expiration
ABILIFY's oppositions filed in EPO
ABILIFY IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9359302 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(3 years ago) | |
| US8642760 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(3 years ago) | |
| US8580796 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8642600 | OTSUKA | Method of treating autism |
Jan, 2022
(4 years ago) | |
| US5006528 | OTSUKA | Carbostyril derivatives |
Oct, 2014
(11 years ago) | |
| US9089567 | OTSUKA | Method of treating cognitive impairments and schizophrenias |
Jan, 2022
(4 years ago) | |
| US7053092 | OTSUKA | 5-HT1a receptor subtype agonist |
Jan, 2022
(4 years ago) | |
| US9387182 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Dec, 2023
(2 years ago) | |
|
US8642600 (Pediatric) | OTSUKA | Method of treating autism |
Jul, 2022
(3 years ago) | |
| US8759350 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Mar, 2027
(1 year, 22 days from now) | |
| US8518421 | OTSUKA | Flashmelt oral dosage formulation |
Jan, 2021
(5 years ago) | |
| US9125939 | OTSUKA | Carbostyril derivatives and mood stabilizers for treating mood disorders |
Jul, 2026
(5 months from now) | |
|
US5006528 (Pediatric) | OTSUKA | Carbostyril derivatives |
Apr, 2015
(10 years ago) | |
|
US8518421 (Pediatric) | OTSUKA | Flashmelt oral dosage formulation |
Jul, 2021
(4 years ago) | |
| US9358207 | OTSUKA | Flashmelt oral dosage formulation |
Apr, 2020
(5 years ago) | |
|
US8642760 (Pediatric) | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Mar, 2023
(2 years ago) | |
|
US8580796 (Pediatric) | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Mar, 2023
(2 years ago) | |
| US8017615 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun, 2024
(1 year, 7 months ago) | |
|
US8017615 (Pediatric) | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Dec, 2024
(1 year, 1 month ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Aug 27, 2011 |
| New Indication(I-616) | Nov 19, 2012 |
| New Indication(I-633) | Feb 16, 2014 |
| M(M-137) | Jun 09, 2017 |
| New Indication(I-700) | Dec 12, 2017 |
| Orphan Drug Exclusivity(ODE) | Dec 12, 2021 |
| Orphan Drug Exclusivity(ODE-80) | Dec 12, 2021 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 15 November, 2002
Treatment: Treatment of irritability associated with autistic disorder; Treatment of schizophrenia including maintaining stability in patients with schizophrenia; Treatment of schizophrenia; Treatment of major d...
Dosage: TABLET; TABLET, ORALLY DISINTEGRATING
How can I launch a generic of ABILIFY before it's drug patent expiration?
More Information on Dosage
ABILIFY family patents
2. Abilify Asimtufii patent expiration
ABILIFY ASIMTUFII's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8399469 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun, 2025
(7 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8759351 | OTSUKA | Methods for administering aripiprazole |
Aug, 2023
(2 years ago) | |
| US8338428 | OTSUKA | Methods for administering aripiprazole |
Aug, 2023
(2 years ago) | |
| US12016927 | OTSUKA | Injectable preparation |
Apr, 2033
(7 years from now) | |
| US11638757 | OTSUKA | Injectable preparation |
Apr, 2033
(7 years from now) | |
| US11097007 | OTSUKA | Injectable preparation |
Apr, 2033
(7 years from now) | |
| US10517951 | OTSUKA | Injectable preparation |
Apr, 2033
(7 years from now) | |
| US8338427 | OTSUKA | Methods for administering aripiprazole |
Mar, 2025
(10 months ago) | |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 27 April, 2023
Treatment: Use of aripiprazole in extended release injectable suspension; Treatment of schizophrenia; Maintenance monotherapy treatment of bipolar i disorder
Dosage: SUSPENSION, EXTENDED RELEASE
More Information on Dosage
ABILIFY ASIMTUFII family patents
3. Abilify Maintena Kit patent
expiration
ABILIFY MAINTENA KIT's oppositions filed in EPO
ABILIFY MAINTENA KIT IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5006528 | OTSUKA | Carbostyril derivatives |
Oct, 2014
(11 years ago) | |
| US8993761 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(3 years ago) | |
| US8399469 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun, 2025
(7 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5006528 (Pediatric) | OTSUKA | Carbostyril derivatives |
Apr, 2015
(10 years ago) | |
| US9089567 | OTSUKA | Method of treating cognitive impairments and schizophrenias |
Jan, 2022
(4 years ago) | |
| US8759351 | OTSUKA | Methods for administering aripiprazole |
Aug, 2023
(2 years ago) | |
| US8338428 | OTSUKA | Methods for administering aripiprazole |
Aug, 2023
(2 years ago) | |
| US5006528 | OTSUKA | Carbostyril derivatives |
Apr, 2015
(10 years ago) | |
| US10525057 | OTSUKA | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Mar, 2034
(8 years from now) | |
| US8338427 | OTSUKA | Methods for administering aripiprazole |
Mar, 2025
(10 months ago) | |
| US11400087 | OTSUKA | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Sep, 2033
(7 years from now) | |
| US7807680 | OTSUKA | Controlled release sterile injectable aripiprazole formulation and method |
Oct, 2024
(1 year, 3 months ago) | |
| US8722679 | OTSUKA | Controlled release sterile injectable aripiprazole formulation and method |
Oct, 2024
(1 year, 3 months ago) | |
| US10980803 | OTSUKA | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Sep, 2033
(7 years from now) | |
| US8030313 | OTSUKA | Controlled release sterile injectable aripiprazole formulation and method |
Oct, 2024
(1 year, 3 months ago) | |
| US11344547 | OTSUKA | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Sep, 2033
(7 years from now) | |
| US11648347 | OTSUKA | Medical device containing a cake composition comprising aripiprazole as an active ingredient, and a cake composition comprising aripiprazole as an active ingredient |
Apr, 2034
(8 years from now) | |
| US11154553 | OTSUKA | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Sep, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Feb 28, 2016 |
| M(M-150) | Dec 05, 2017 |
| New Indication(I-746) | Jul 27, 2020 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 28 February, 2013
Treatment: Treatment of schizophrenia; Use of aripiprazole in extended release injectable suspension; Use of aripiprazole in extended release injectable suspension in treating acute episodes of schizophrenia; Tr...
Dosage: FOR SUSPENSION, EXTENDED RELEASE
How can I launch a generic of ABILIFY MAINTENA KIT before it's drug patent expiration?
More Information on Dosage
ABILIFY MAINTENA KIT family patents
4. Abilify Mycite Kit patent expiration
ABILIFY MYCITE KIT's oppositions filed in EPO
ABILIFY MYCITE KIT IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9359302 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(3 years ago) | |
| US8580796 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(3 years ago) | |
| US8642760 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9787511 | OTSUKA | Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping |
Sep, 2034
(8 years from now) | |
| US9089567 | OTSUKA | Method of treating cognitive impairments and schizophrenias |
Jan, 2022
(4 years ago) | |
| US9387182 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Dec, 2023
(2 years ago) | |
| US9270503 | OTSUKA | Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping |
Sep, 2034
(8 years from now) | |
| US9577864 | OTSUKA | Method and apparatus for use with received electromagnetic signal at a frequency not known exactly in advance |
Oct, 2033
(7 years from now) | |
| US10097388 | OTSUKA | Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping |
Sep, 2034
(8 years from now) | |
| US7053092 | OTSUKA | 5-HT1a receptor subtype agonist |
Jan, 2022
(4 years ago) | |
| US8956288 | OTSUKA | In-body power source having high surface area electrode |
Jul, 2029
(3 years from now) | |
| US9268909 | OTSUKA | Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device |
Oct, 2033
(7 years from now) | |
| US8759350 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Mar, 2027
(1 year, 22 days from now) | |
| US9125939 | OTSUKA | Carbostyril derivatives and mood stabilizers for treating mood disorders |
Jul, 2026
(5 months from now) | |
| US8674825 | OTSUKA | Pharma-informatics system |
Apr, 2029
(3 years from now) | |
| US8945005 | OTSUKA | Controlled activation ingestible identifier |
Aug, 2029
(3 years from now) | |
| US9444503 | OTSUKA | Active signal processing personal health signal receivers |
Nov, 2027
(1 year, 9 months from now) | |
| US8547248 | OTSUKA | Implantable zero-wire communications system |
Dec, 2030
(4 years from now) | |
| US8847766 | OTSUKA | Pharma-informatics system |
Mar, 2030
(4 years from now) | |
| US8017615 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun, 2024
(1 year, 7 months ago) | |
| US9433371 | OTSUKA | In-body device with virtual dipole signal amplification |
Sep, 2029
(3 years from now) | |
| US7978064 | OTSUKA | Communication system with partial power source |
Sep, 2026
(7 months from now) | |
| US9119554 | OTSUKA | Pharma-informatics system |
Dec, 2028
(2 years from now) | |
| US8114021 | OTSUKA | Body-associated receiver and method |
Jun, 2030
(4 years from now) | |
| US11229378 | OTSUKA | Communication system with enhanced partial power source and method of manufacturing same |
Jul, 2031
(5 years from now) | |
| US11464423 | OTSUKA | In-body power source having high surface area electrode |
Sep, 2030
(4 years from now) | |
| US8258962 | OTSUKA | Multi-mode communication ingestible event markers and systems, and methods of using the same |
Nov, 2030
(4 years from now) | |
| US8961412 | OTSUKA | In-body device with virtual dipole signal amplification |
Nov, 2030
(4 years from now) | |
| US9060708 | OTSUKA | Multi-mode communication ingestible event markers and systems, and methods of using the same |
Mar, 2029
(3 years from now) | |
| US10441194 | OTSUKA | Ingestible event marker systems |
Jul, 2029
(3 years from now) | |
| US9320455 | OTSUKA | Highly reliable ingestible event markers and methods for using the same |
Dec, 2031
(5 years from now) | |
| US8718193 | OTSUKA | Active signal processing personal health signal receivers |
Dec, 2029
(3 years from now) | |
| US9149577 | OTSUKA | Body-associated receiver and method |
Dec, 2029
(3 years from now) | |
| US9258035 | OTSUKA | Multi-mode communication ingestible event markers and systems, and methods of using the same |
Mar, 2029
(3 years from now) | |
| US11476952 | OTSUKA | Pharma-informatics system |
Apr, 2026
(2 months from now) | |
| US10517507 | OTSUKA | Communication system with enhanced partial power source and method of manufacturing same |
Jun, 2032
(6 years from now) | |
| US8545402 | OTSUKA | Highly reliable ingestible event markers and methods for using the same |
Apr, 2030
(4 years from now) | |
| US9941931 | OTSUKA | System for supply chain management |
Nov, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-150) | Dec 05, 2017 |
| New Indication(I-746) | Jul 27, 2020 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 13 November, 2017
Treatment: Method of using a receiver to identify a signal from a tablet embedded with a sensor that communicates information through the body of a patient; Treatment of schizophrenia; Adjunctive treatment of ma...
Dosage: TABLET
More Information on Dosage
ABILIFY MYCITE KIT family patents
5. Adasuve patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9687487 | NOVA PNEUMA | Aerosol forming device for use in inhalation therapy |
Oct, 2021
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8074644 | NOVA PNEUMA | Method of forming an aerosol for inhalation delivery |
Oct, 2021
(4 years ago) | |
| US7585493 | NOVA PNEUMA | Thin-film drug delivery article and method of use |
Oct, 2021
(4 years ago) | |
| US7601337 | NOVA PNEUMA | Delivery of antipsychotics through an inhalation route |
Oct, 2021
(4 years ago) | |
| US8387612 | NOVA PNEUMA | Self-contained heating unit and drug-supply unit employing same |
Oct, 2026
(8 months from now) | |
| US8235037 | NOVA PNEUMA | Drug condensation aerosols and kits |
Oct, 2021
(4 years ago) | |
| US7458374 | NOVA PNEUMA | Method and apparatus for vaporizing a compound |
Aug, 2024
(1 year, 5 months ago) | |
| US9370629 | NOVA PNEUMA | Self-contained heating unit and drug-supply unit employing same |
May, 2024
(1 year, 8 months ago) | |
| US8173107 | NOVA PNEUMA | Delivery of antipsychotics through an inhalation route |
Oct, 2021
(4 years ago) | |
| US7078020 | NOVA PNEUMA | Delivery of antipsychotics through an inhalation route |
Oct, 2021
(4 years ago) | |
| US6716416 | NOVA PNEUMA | Delivery of antipsychotics through an inhalation route |
May, 2022
(3 years ago) | |
| US9439907 | NOVA PNEUMA | Method of forming an aerosol for inhalation delivery |
Oct, 2021
(4 years ago) | |
| US7537009 | NOVA PNEUMA | Method of forming an aerosol for inhalation delivery |
Oct, 2024
(1 year, 3 months ago) | |
| US8955512 | NOVA PNEUMA | Method of forming an aerosol for inhalation delivery |
Oct, 2021
(4 years ago) | |
| US7052679 | NOVA PNEUMA | Delivery of antipsychotics through an inhalation route |
Mar, 2022
(3 years ago) | |
| US7090830 | NOVA PNEUMA | Drug condensation aerosols and kits |
Oct, 2021
(4 years ago) | |
| US8991387 | NOVA PNEUMA | Self-contained heating unit and drug-supply unit employing same |
May, 2024
(1 year, 8 months ago) | |
| US9440034 | NOVA PNEUMA | Drug condensation aerosols and kits |
Oct, 2021
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Dec 21, 2015 |
Drugs and Companies using LOXAPINE ingredient
Market Authorisation Date: 21 December, 2012
Treatment: Adasuve is a typical antipsychotic indicated for the acute treatment of agitation associated with schizophrenia or bipolar i disorder in adults
Dosage: POWDER
More Information on Dosage
ADASUVE family patents
6. Addyi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7420057 | SPROUT | Stable polymorph of flibanserin |
Aug, 2022
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8227471 | SPROUT | Treating sexual desire disorders with flibanserin |
May, 2023
(2 years ago) | |
| US9468639 | SPROUT | Treating sexual desire disorders with flibanserin |
Oct, 2022
(3 years ago) | |
| US7151103 | SPROUT | Method of treating female hypoactive sexual desire disorder with flibanserin |
May, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 18, 2020 |
Drugs and Companies using FLIBANSERIN ingredient
NCE-1 date: 19 August, 2019
Market Authorisation Date: 18 August, 2015
Treatment: Use of flibanserin or a pharmaceutically acceptable acid addition salt thereof to treat hypoactive sexual desire disorder (hsdd)
Dosage: TABLET
More Information on Dosage
ADDYI family patents
7. Adlyxin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE45313 | SANOFI | Exendin variant peptides |
Jul, 2020
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9821032 | SANOFI | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
May, 2032
(6 years from now) | |
| US10201663 | SANOFI | Assembly for a drug delivery device |
Mar, 2034
(8 years from now) | |
| US8475414 | SANOFI | Medication delivery device and method for operating a medication delivery device |
Dec, 2030
(4 years from now) | |
| US9308329 | SANOFI | Medication delivery device and method for operating a medication delivery device |
Dec, 2030
(4 years from now) | |
| US8915888 | SANOFI | Dosing and drive mechanism for drug delivery device |
Jun, 2030
(4 years from now) | |
| US9981013 | SANOFI | Use of AVE0010 for the treatment of diabetes mellitus type 2 |
Aug, 2030
(4 years from now) | |
| US9408893 | SANOFI | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
Aug, 2032
(6 years from now) | |
| US9084853 | SANOFI | Drive mechanism for a drug delivery device and drug delivery device |
Oct, 2031
(5 years from now) | |
| US9855388 | SANOFI | Dosing and drive mechanism for drug delivery device |
Apr, 2029
(3 years from now) | |
| US9072836 | SANOFI | Drive mechanism for a drug delivery device and drug delivery device |
Mar, 2032
(6 years from now) | |
| US9440029 | SANOFI | Drive mechanism for a drug delivery device and drug delivery device |
Jan, 2032
(5 years from now) | |
| US9511193 | SANOFI | Assembly and indicator for a drug delivery device |
Jan, 2032
(5 years from now) | |
| US9707176 | SANOFI | Pharmaceutical composition comprising a GLP-1 agonist and methionine |
Nov, 2030
(4 years from now) | |
| US10028910 | SANOFI | Pharmaceutical composition comprising a GLP-1-agonist and methionine |
Nov, 2030
(4 years from now) | |
| US8882721 | SANOFI | Drive assembly suitable for use in a drug delivery device and drug delivery device |
Jun, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 27, 2021 |
Drugs and Companies using LIXISENATIDE ingredient
NCE-1 date: 27 July, 2020
Market Authorisation Date: 27 July, 2016
Treatment: Combination treatment with insulin glargine with or without metformin for improvement of glycemic control in type 2 diabetes mellitus patients; Improvement in glycemic control in type 2 diabetes melli...
Dosage: SOLUTION
More Information on Dosage
ADLYXIN family patents
8. Aggrastat patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5733919 | MEDICURE | Compositions for inhibiting platelet aggregation |
Oct, 2016
(9 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6136794 | MEDICURE | Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist |
Jan, 2019
(7 years ago) | |
| US5978698 | MEDICURE | Angioplasty procedure using nonionic contrast media |
Oct, 2017
(8 years ago) | |
| US5733919 | MEDICURE | Compositions for inhibiting platelet aggregation |
Oct, 2016
(9 years ago) | |
| US5972967 | MEDICURE | Compositions for inhibiting platelet aggregation |
Oct, 2016
(9 years ago) | |
| US5965581 | MEDICURE | Compositions for inhibiting platelet aggregation |
Oct, 2016
(9 years ago) | |
| US6770660 | MEDICURE | Method for inhibiting platelet aggregation |
May, 2023
(2 years ago) | |
Drugs and Companies using TIROFIBAN HYDROCHLORIDE ingredient
Market Authorisation Date: 14 May, 1998
Treatment: A dosing regimen of aggrastat (tirofiban hydrochloride)(25mcg/kg followed by 0.15mcg/kg/min infusion) to reduce the rate of thrombotic coronary events associated with acute coronary syndrome (acs) in ...
Dosage: SOLUTION; INJECTABLE
How can I launch a generic of AGGRASTAT before it's drug patent expiration?
More Information on Dosage
AGGRASTAT family patents
9. Arcapta Neohaler patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8658673 | NOVARTIS | BETA2-adrenoreceptor agonists |
Jun, 2020
(5 years ago) | |
| US8796307 | NOVARTIS | Beta2-adrenoreceptor agonists |
Jun, 2020
(5 years ago) | |
| US6878721 | NOVARTIS | Beta2-adrenoceptor agonists |
Feb, 2025
(11 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8067437 | NOVARTIS | Beta-2-adrenoreceptor agonists |
Jun, 2020
(5 years ago) | |
| US8479730 | NOVARTIS | Inhaler device |
Oct, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 01, 2016 |
Drugs and Companies using INDACATEROL MALEATE ingredient
NCE-1 date: 02 July, 2015
Market Authorisation Date: 01 July, 2011
Treatment: The long term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema
Dosage: POWDER
More Information on Dosage
ARCAPTA NEOHALER family patents
10. Arnuity Ellipta patent expiration
ARNUITY ELLIPTA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7101866 | GLAXOSMITHKLINE | Anti-inflammatory androstane derivative |
Aug, 2021
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8113199 | GLAXOSMITHKLINE | Counter for use with a medicament dispenser |
Oct, 2027
(1 year, 8 months from now) | |
| US5873360 | GLAXOSMITHKLINE | Inhalation device |
Feb, 2016
(9 years ago) | |
| US7629335 | GLAXOSMITHKLINE | Anti-inflammatory androstane derivative |
Aug, 2021
(4 years ago) | |
| US8161968 | GLAXOSMITHKLINE | Medicament dispenser |
Feb, 2028
(1 year, 11 months from now) | |
|
US8161968 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Aug, 2028
(2 years from now) | |
|
US8113199 (Pediatric) | GLAXOSMITHKLINE | Counter for use with a medicament dispenser |
Apr, 2028
(2 years from now) | |
|
US8534281 (Pediatric) | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Sep, 2030
(4 years from now) | |
| US8534281 | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Mar, 2030
(4 years from now) | |
| US8201556 | GLAXOSMITHKLINE | Medicament dispenser |
Feb, 2029
(2 years from now) | |
| US9333310 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2027
(1 year, 7 months from now) | |
| US8746242 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2030
(4 years from now) | |
|
US8746242 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Apr, 2031
(5 years from now) | |
|
US9333310 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Apr, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 20, 2017 |
| New Patient Population(NPP) | May 17, 2021 |
| New Strength(NS) | May 17, 2021 |
| M(M-290) | Mar 01, 2026 |
Drugs and Companies using FLUTICASONE FUROATE ingredient
Market Authorisation Date: 17 May, 2018
Treatment: Indicated for the once-daily maintenance treatment of asthma as prophylactic therapy in patients aged 12 years of age and older
Dosage: POWDER
More Information on Dosage
ARNUITY ELLIPTA family patents
11. Auryxia patent expiration
AURYXIA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9328133 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(1 year, 11 months ago) | |
| US8338642 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(1 year, 11 months ago) | |
| US9757416 | KERYX BIOPHARMS | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(1 year, 11 months ago) | |
| US7767851 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(1 year, 11 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5753706 | KERYX BIOPHARMS | Methods for treating renal failure |
Feb, 2022
(4 years ago) | |
| US8093423 | KERYX BIOPHARMS | Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same |
Apr, 2026
(2 months from now) | |
| US10300039 | KERYX BIOPHARMS | Ferric citrate dosage forms |
Jul, 2030
(4 years from now) | |
| US8846976 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(1 year, 11 months ago) | |
| US8901349 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(1 year, 11 months ago) | |
| US8609896 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(1 year, 11 months ago) | |
| US8299298 | KERYX BIOPHARMS | Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same |
Feb, 2024
(1 year, 11 months ago) | |
| US8754258 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(1 year, 11 months ago) | |
| US8754257 | KERYX BIOPHARMS | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(1 year, 11 months ago) | |
| US9050316 | KERYX BIOPHARMS | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(1 year, 11 months ago) | |
| US9387191 | KERYX BIOPHARMS | Ferric citrate dosage forms |
Jul, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-790) | Nov 06, 2020 |
Drugs and Companies using FERRIC CITRATE ingredient
Market Authorisation Date: 05 September, 2014
Treatment: Control of serum phosphorous levels; Control of serum phosphorus levels
Dosage: TABLET
More Information on Dosage
AURYXIA family patents
12. Axumin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5808146 | BLUE EARTH | Amino acid analogs for tumor imaging |
Nov, 2020
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9387266 | BLUE EARTH | Precursor compound of radioactive halogen-labeled organic compound |
Nov, 2026
(9 months from now) | |
| US10716868 | BLUE EARTH | Imaging of metastatic or recurrent cancer |
Dec, 2035
(9 years from now) | |
| US10953112 | BLUE EARTH | Precursor compound of radioactive halogen-labeled organic compound |
Nov, 2026
(9 months from now) | |
| US10967077 | BLUE EARTH | Imaging of metastatic or recurrent cancer |
Dec, 2035
(9 years from now) | |
| US10124079 | BLUE EARTH | Imaging of metastatic or recurrent cancer |
Dec, 2035
(9 years from now) | |
| US10933147 | BLUE EARTH | Imaging of metastatic or recurrent cancer |
Dec, 2035
(9 years from now) | |
| US11980674 | BLUE EARTH | Imaging of metastatic or recurrent cancer |
Apr, 2042
(16 years from now) | |
| US10010632 | BLUE EARTH | Precursor compound of radioactive halogen-labeled organic compound |
Nov, 2026
(9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 27, 2021 |
Drugs and Companies using FLUCICLOVINE F-18 ingredient
NCE-1 date: 27 May, 2020
Market Authorisation Date: 27 May, 2016
Treatment: Method of diagnosing tumors using positron emission tomography; Positron emission tomography diagnostic agent in adults with suspected prostate cancer recurrence based on elevated blood prostate speci...
Dosage: SOLUTION
More Information on Dosage
AXUMIN family patents
13. Breo Ellipta patent expiration
BREO ELLIPTA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE44874 | GLAXO | Phenethanolamine derivatives for treatment of respiratory diseases |
Mar, 2023
(2 years ago) | |
| US7101866 | GLAXO | Anti-inflammatory androstane derivative |
Aug, 2021
(4 years ago) | |
| US7439393 | GLAXO | Phenethanolamine derivatives for treatment of respiratory diseases |
May, 2025
(8 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7361787 | GLAXO | Phenethanolamine derivatives for treatment of respiratory diseases |
Mar, 2023
(2 years ago) | |
| US7629335 | GLAXO | Anti-inflammatory androstane derivative |
Aug, 2021
(4 years ago) | |
| US6759398 | GLAXO | Anti-inflammatory androstane derivative |
Aug, 2021
(4 years ago) | |
| US6537983 | GLAXO | Anti-inflammatory androstane derivatives |
Aug, 2021
(4 years ago) | |
| US5873360 | GLAXO | Inhalation device |
Feb, 2016
(9 years ago) | |
| US6878698 | GLAXO | Anti-inflammatory androstane derivatives |
Aug, 2021
(4 years ago) | |
| US7101866 | GLAXO | Anti-inflammatory androstane derivative |
Aug, 2021
(4 years ago) | |
| US7776895 | GLAXO | Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases |
Sep, 2022
(3 years ago) | |
| US8113199 | GLAXO | Counter for use with a medicament dispenser |
Oct, 2027
(1 year, 8 months from now) | |
|
US8113199 (Pediatric) | GLAXO | Counter for use with a medicament dispenser |
Apr, 2028
(2 years from now) | |
| US8511304 | GLAXO | Medicament dispenser |
Jun, 2027
(1 year, 4 months from now) | |
| US8746242 | GLAXO | Medicament dispenser |
Oct, 2030
(4 years from now) | |
| US11116721 | GLAXO | Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol |
Feb, 2029
(3 years from now) | |
| US8161968 | GLAXO | Medicament dispenser |
Feb, 2028
(1 year, 11 months from now) | |
| US9333310 | GLAXO | Medicament dispenser |
Oct, 2027
(1 year, 7 months from now) | |
|
US8161968 (Pediatric) | GLAXO | Medicament dispenser |
Aug, 2028
(2 years from now) | |
|
US9333310 (Pediatric) | GLAXO | Medicament dispenser |
Apr, 2028
(2 years from now) | |
| US8534281 | GLAXO | Manifold for use in medicament dispenser |
Mar, 2030
(4 years from now) | |
|
US7439393 (Pediatric) | GLAXO | Phenethanolamine derivatives for treatment of respiratory diseases |
Nov, 2025
(2 months ago) | |
|
US8746242 (Pediatric) | GLAXO | Medicament dispenser |
Apr, 2031
(5 years from now) | |
|
US8534281 (Pediatric) | GLAXO | Manifold for use in medicament dispenser |
Sep, 2030
(4 years from now) | |
|
US8511304 (Pediatric) | GLAXO | Medicament dispenser |
Dec, 2027
(1 year, 10 months from now) | |
|
US11116721 (Pediatric) | GLAXO | Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol |
Aug, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 30, 2018 |
| New Indication(I-708) | Apr 30, 2018 |
| New Chemical Entity Exclusivity(NCE) | May 10, 2018 |
| M(M-202) | May 15, 2020 |
| New Patient Population(NPP) | May 13, 2026 |
| New Strength(NS) | May 13, 2026 |
| Pediatric Exclusivity(PED) | Nov 13, 2026 |
Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient
NCE-1 date: 13 November, 2025
Market Authorisation Date: 12 May, 2023
Treatment: Indicated for long-term, once-daily maintenance treatment of airflow obstruction in pts with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in pts with a his...
Dosage: POWDER
More Information on Dosage
BREO ELLIPTA family patents
14. Bridion patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE44733 | MERCK | 6-mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block |
Jan, 2026
(11 days ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6949527 | MERCK | 6-Mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block |
Jan, 2021
(5 years ago) | |
| US7265099 | MERCK | Use of chemical chelators as reversal agents for drug-induced neuromuscular block |
Aug, 2020
(5 years ago) | |
| US7265009 | MERCK | HDP-CVD methodology for forming PMD layer |
Aug, 2020
(5 years ago) | |
|
USRE44733 (Pediatric) | MERCK | 6-mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block |
Jul, 2026
(5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 15, 2020 |
| M(M-262) | Jun 09, 2023 |
| M(M-291) | Jan 22, 2024 |
| New Patient Population(NPP) | Dec 12, 2027 |
| Pediatric Exclusivity(PED) | Jun 12, 2028 |
Drugs and Companies using SUGAMMADEX SODIUM ingredient
NCE-1 date: 13 June, 2027
Market Authorisation Date: 15 December, 2015
Treatment: Reversal of neuromuscular blockage induced by rocuronium bromide or vecuronium bromide; Reversal of drug-induced neuromuscular block
Dosage: SOLUTION
How can I launch a generic of BRIDION before it's drug patent expiration?
More Information on Dosage
BRIDION family patents
15. Brilinta patent expiration
BRILINTA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7250419 | ASTRAZENECA | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition |
Dec, 2019
(6 years ago) | |
| US7265124 | ASTRAZENECA | Cristalline and amorphous form of a triazolo (4,5-D) pyridimine compound |
Jul, 2021
(4 years ago) | |
| US6525060 | ASTRAZENECA | Triazolo(4,5-d)pyrimidine compounds |
Dec, 2019
(6 years ago) | |
| US6251910 | ASTRAZENECA | 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists |
Jul, 2018
(7 years ago) | |
| USRE46276 | ASTRAZENECA | Triazolo(4,5-D)pyrimidine compounds |
Oct, 2024
(1 year, 3 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6525060 | ASTRAZENECA | Triazolo(4,5-d)pyrimidine compounds |
Dec, 2019
(6 years ago) | |
| US6251910 | ASTRAZENECA | 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists |
Jul, 2018
(7 years ago) | |
| US7250419 | ASTRAZENECA | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition |
Dec, 2019
(6 years ago) | |
| US7265124 | ASTRAZENECA | Cristalline and amorphous form of a triazolo (4,5-D) pyridimine compound |
Jul, 2021
(4 years ago) | |
| US10300065 | ASTRAZENECA | Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction |
Jan, 2036
(9 years from now) | |
| US8425934 | ASTRAZENECA | Pharmaceutical compositions |
Apr, 2030
(4 years from now) | |
|
US8425934 (Pediatric) | ASTRAZENECA | Pharmaceutical compositions |
Oct, 2030
(4 years from now) | |
|
USRE46276 (Pediatric) | ASTRAZENECA | Triazolo(4,5-D)pyrimidine compounds |
Apr, 2025
(9 months ago) | |
|
US10300065 (Pediatric) | ASTRAZENECA | Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction |
Jul, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2016 |
| New Indication(I-714) | Sep 03, 2018 |
| New Strength(NS) | Sep 03, 2018 |
| New Indication(I-851) | May 28, 2023 |
| New Indication(I-848) | Nov 05, 2023 |
| M(M-283) | May 09, 2025 |
| Pediatric Exclusivity(PED) | Nov 09, 2025 |
Drugs and Companies using TICAGRELOR ingredient
NCE-1 date: 09 November, 2024
Market Authorisation Date: 03 September, 2015
Treatment: Reduction of the rate of thrombotic events in patients with acute coronary syndrome; Reducing the rate of cardiovascular death, myocardial infarction, and stroke in a patient receiving 75-100 mg aspir...
Dosage: TABLET
How can I launch a generic of BRILINTA before it's drug patent expiration?
More Information on Dosage
BRILINTA family patents
16. Bydureon Bcise patent expiration
BYDUREON BCISE's oppositions filed in EPO
BYDUREON BCISE IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6515117 | ASTRAZENECA | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2025
(4 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6956026 | ASTRAZENECA | Use of exendins for the reduction of food intake |
Jan, 2018
(8 years ago) | |
| US9198925 | ASTRAZENECA | Pharmaceutical formulations containing an SGLT2 inhibitor |
Oct, 2020
(5 years ago) | |
| US6414126 | ASTRAZENECA | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2020
(5 years ago) | |
| US6936590 | ASTRAZENECA | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2020
(5 years ago) | |
| US6872700 | ASTRAZENECA | Methods for glucagon suppression |
Jan, 2020
(6 years ago) | |
| US6479065 | ASTRAZENECA | Process for the preparation of polymer-based sustained release compositions |
Aug, 2020
(5 years ago) | |
| US6667061 | ASTRAZENECA | Preparation of injectable suspensions having improved injectability |
May, 2020
(5 years ago) | |
| US7741269 | ASTRAZENECA | Exendins and exendin agonists for weight reduction and obesity |
Jan, 2018
(8 years ago) | |
| US7223440 | ASTRAZENECA | Residual solvent extraction method and microparticles produced thereby |
Aug, 2021
(4 years ago) | |
|
US6824822 (Pediatric) | ASTRAZENECA | Residual solvent extraction method and microparticles produced thereby |
Apr, 2023
(2 years ago) | |
| US6824822 | ASTRAZENECA | Residual solvent extraction method and microparticles produced thereby |
Oct, 2022
(3 years ago) | |
|
US7223440 (Pediatric) | ASTRAZENECA | Residual solvent extraction method and microparticles produced thereby |
Mar, 2022
(3 years ago) | |
| US9238076 | ASTRAZENECA | Polymer-based sustained release device |
Apr, 2024
(1 year, 9 months ago) | |
| US7456254 | ASTRAZENECA | Polymer-based sustained release device |
Jun, 2025
(7 months ago) | |
| US7612176 | ASTRAZENECA | Polymer-based sustained release device |
Apr, 2025
(9 months ago) | |
| US8461105 | ASTRAZENECA | Polymer-based sustained release device |
Apr, 2025
(9 months ago) | |
| US8906851 | ASTRAZENECA | Method for treating diabetes |
Aug, 2026
(6 months from now) | |
| US9884092 | ASTRAZENECA | Methods for treating diabetes and reducing body weight |
Aug, 2026
(6 months from now) | |
|
US7563871 (Pediatric) | ASTRAZENECA | Polymer-based sustained release device |
Oct, 2024
(1 year, 3 months ago) | |
|
US9238076 (Pediatric) | ASTRAZENECA | Polymer-based sustained release device |
Oct, 2024
(1 year, 3 months ago) | |
| US8329648 | ASTRAZENECA | Methods for treating diabetes and reducing body weight |
Aug, 2026
(6 months from now) | |
| US8431685 | ASTRAZENECA | Polymer-based sustained release device |
Apr, 2025
(9 months ago) | |
| US8895033 | ASTRAZENECA | Sustained release formulations using non-aqueous carriers |
Oct, 2030
(4 years from now) | |
| US7563871 | ASTRAZENECA | Polymer-based sustained release device |
Apr, 2024
(1 year, 9 months ago) | |
| US8501698 | ASTRAZENECA | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(1 year, 4 months from now) | |
| US8361972 | ASTRAZENECA | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(2 years from now) | |
|
US7612176 (Pediatric) | ASTRAZENECA | Polymer-based sustained release device |
Oct, 2025
(3 months ago) | |
|
US7456254 (Pediatric) | ASTRAZENECA | Polymer-based sustained release device |
Dec, 2025
(a month ago) | |
|
US8329648 (Pediatric) | ASTRAZENECA | Methods for treating diabetes and reducing body weight |
Feb, 2027
(1 year, 10 days from now) | |
|
US8431685 (Pediatric) | ASTRAZENECA | Polymer-based sustained release device |
Oct, 2025
(3 months ago) | |
|
US8461105 (Pediatric) | ASTRAZENECA | Polymer-based sustained release device |
Oct, 2025
(3 months ago) | |
|
US8895033 (Pediatric) | ASTRAZENECA | Sustained release formulations using non-aqueous carriers |
Apr, 2031
(5 years from now) | |
|
US8906851 (Pediatric) | ASTRAZENECA | Method for treating diabetes |
Feb, 2027
(1 year, 10 days from now) | |
|
US9884092 (Pediatric) | ASTRAZENECA | Methods for treating diabetes and reducing body weight |
Feb, 2027
(1 year, 10 days from now) | |
|
US8501698 (Pediatric) | ASTRAZENECA | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2027
(1 year, 10 months from now) | |
|
US6515117 (Pediatric) | ASTRAZENECA | C-aryl glucoside SGLT2 inhibitors and method |
Apr, 2026
(a month from now) | |
|
US8361972 (Pediatric) | ASTRAZENECA | Pharmaceutical formulations containing an SGLT2 inhibitor |
Sep, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 20, 2020 |
| M(M-240) | Feb 15, 2022 |
| New Patient Population(NPP) | Jul 22, 2024 |
| Pediatric Exclusivity(PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 20 October, 2017
Treatment: Reducing food intake in a subject with type 2 diabetes by administering an exendin, such as exendin-4; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes me...
Dosage: SUSPENSION, EXTENDED RELEASE
More Information on Dosage
BYDUREON BCISE family patents
17. Cresemba patent expiration
CRESEMBA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7459561 | ASTELLAS | N-substituted carbamoyloxyalkyl-azolium derivatives |
Oct, 2020
(5 years ago) | |
| US10812238 | ASTELLAS | Configurable reference signals |
Oct, 2025
(3 months ago) | |
| US6812238 | ASTELLAS | N-substituted carbamoyloxyalkyl-azolium derivatives |
Oct, 2025
(3 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10603280 | ASTELLAS | Active ingredient containing stabilised solid medicinal forms and methods for the production thereof |
Sep, 2027
(1 year, 7 months from now) | |
| US10206879 | ASTELLAS | Active ingredient containing stabilised solid forms and method for the production thereof |
Sep, 2027
(1 year, 7 months from now) | |
|
US6812238 (Pediatric) | ASTELLAS | N-substituted carbamoyloxyalkyl-azolium derivatives |
Apr, 2026
(2 months from now) | |
|
US10603280 (Pediatric) | ASTELLAS | Active ingredient containing stabilised solid medicinal forms and methods for the production thereof |
Mar, 2028
(2 years from now) | |
|
US10206879 (Pediatric) | ASTELLAS | Active ingredient containing stabilised solid forms and method for the production thereof |
Mar, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 06, 2020 |
| Orphan Drug Exclusivity(ODE) | Mar 06, 2022 |
| ODE*(ODE*) | Mar 06, 2022 |
| Orphan Drug Exclusivity(ODE-305) | Mar 06, 2022 |
| Orphan Drug Exclusivity(ODE-90) | Mar 06, 2022 |
| New Patient Population(NPP) | Dec 08, 2026 |
| Generating Antibiotic Incentives Now(GAIN) | Sep 06, 2027 |
| Orphan Drug Exclusivity(ODE-453) | Dec 08, 2030 |
| Orphan Drug Exclusivity(ODE-454) | Dec 08, 2030 |
| Orphan Drug Exclusivity(ODE-458) | Dec 08, 2030 |
| Orphan Drug Exclusivity(ODE-459) | Dec 08, 2030 |
| Pediatric Exclusivity(PED) | Jun 08, 2031 |
Drugs and Companies using ISAVUCONAZONIUM SULFATE ingredient
NCE-1 date: 08 June, 2030
Market Authorisation Date: 06 March, 2015
Treatment: NA
Dosage: POWDER; CAPSULE
More Information on Dosage
CRESEMBA family patents
18. Daliresp patent expiration
DALIRESP's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5712298 | ASTRAZENECA | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors |
Jan, 2020
(6 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8536206 | ASTRAZENECA | Process for the preparation of roflumilast |
Mar, 2024
(1 year, 11 months ago) | |
| US8431154 | ASTRAZENECA | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient |
Feb, 2023
(2 years ago) | |
| US9468598 | ASTRAZENECA | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
Feb, 2023
(2 years ago) | |
| US5712298 | ASTRAZENECA | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors |
Jan, 2015
(11 years ago) | |
| US8604064 | ASTRAZENECA | Process for the preparation of roflumilast |
Mar, 2024
(1 year, 11 months ago) | |
| US8618142 | ASTRAZENECA | Process for the preparation of roflumilast |
Mar, 2024
(1 year, 11 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 28, 2016 |
| M(M-208) | Aug 31, 2020 |
| New Dosing Schedule(D-171) | Jan 23, 2021 |
| New Strength(NS) | Jan 23, 2021 |
Drugs and Companies using ROFLUMILAST ingredient
NCE-1 date: 28 February, 2015
Market Authorisation Date: 23 January, 2018
Treatment: Treatment to reduce the risk of copd exacerbations in patients with severe copd associated with chronic bronchitis and a history of exacerbations
Dosage: TABLET
How can I launch a generic of DALIRESP before it's drug patent expiration?
More Information on Dosage
DALIRESP family patents
19. Dexilant patent expiration
DEXILANT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9145389 | TAKEDA | Benzimidazole compound crystal |
Jun, 2020
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6939971 | TAKEDA | Benzimidazole compound crystal |
Jun, 2020
(5 years ago) | |
| US6462058 | TAKEDA | Benzimidazole compound crystal |
Jun, 2020
(5 years ago) | |
| US8784885 | TAKEDA | Controlled release preparation |
Oct, 2023
(2 years ago) | |
| US6664276 | TAKEDA | Benzimidazole compound crystal |
Jun, 2020
(5 years ago) | |
| US7285668 | TAKEDA | Process for the crystallization of (R)- or (S)-lansoprazole |
Jun, 2020
(5 years ago) | |
|
US7285668 (Pediatric) | TAKEDA | Process for the crystallization of (R)- or (S)-lansoprazole |
Dec, 2020
(5 years ago) | |
|
US6462058 (Pediatric) | TAKEDA | Benzimidazole compound crystal |
Dec, 2020
(5 years ago) | |
|
US6939971 (Pediatric) | TAKEDA | Benzimidazole compound crystal |
Dec, 2020
(5 years ago) | |
| US8722084 | TAKEDA | Controlled release preparation |
Oct, 2023
(2 years ago) | |
| US9233103 | TAKEDA | Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy |
Mar, 2032
(6 years from now) | |
|
US6664276 (Pediatric) | TAKEDA | Benzimidazole compound crystal |
Dec, 2020
(5 years ago) | |
| US8173158 | TAKEDA | Methods of treating gastrointestinal disorders independent of the intake of food |
Mar, 2030
(4 years from now) | |
|
US8784885 (Pediatric) | TAKEDA | Controlled release preparation |
Apr, 2024
(1 year, 9 months ago) | |
|
US8722084 (Pediatric) | TAKEDA | Controlled release preparation |
Apr, 2024
(1 year, 9 months ago) | |
| US9011926 | TAKEDA | Method for producing granules |
Feb, 2026
(16 days from now) | |
| US7790755 | TAKEDA | Controlled release preparation |
Aug, 2026
(5 months from now) | |
| US9238029 | TAKEDA | Multiple PPI dosage form |
Jan, 2026
(21 days ago) | |
| US8871273 | TAKEDA | Method for producing granules |
Jan, 2028
(1 year, 11 months from now) | |
| US8105626 | TAKEDA | Granules containing acid-unstable chemical in large amount |
Sep, 2026
(7 months from now) | |
| US8461187 | TAKEDA | Multiple PPI dosage form |
Jan, 2026
(21 days ago) | |
|
US7790755 (Pediatric) | TAKEDA | Controlled release preparation |
Feb, 2027
(11 months from now) | |
|
US8105626 (Pediatric) | TAKEDA | Granules containing acid-unstable chemical in large amount |
Mar, 2027
(1 year, 1 month from now) | |
|
US8173158 (Pediatric) | TAKEDA | Methods of treating gastrointestinal disorders independent of the intake of food |
Sep, 2030
(4 years from now) | |
|
US8461187 (Pediatric) | TAKEDA | Multiple PPI dosage form |
Jul, 2026
(5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 30, 2012 |
| Pediatric Exclusivity(PED) | Jul 30, 2012 |
| New Patient Population(NPP) | Jul 08, 2019 |
Drugs and Companies using DEXLANSOPRAZOLE ingredient
Market Authorisation Date: 30 January, 2009
Treatment: Healing of all grades of erosive esophagitis (ee) for up to 8 weeks; Maintain healing of erosive esophagitis (ee) for up to 6 months; For the treatment of heartburn associated with symptomatic non-ero...
Dosage: CAPSULE, DELAYED RELEASE
How can I launch a generic of DEXILANT before it's drug patent expiration?
More Information on Dosage
DEXILANT family patents
20. Dexilant Solutab patent expiration
DEXILANT SOLUTAB's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6462058 | TAKEDA | Benzimidazole compound crystal |
Jun, 2020
(5 years ago) | |
| US9145389 | TAKEDA | Benzimidazole compound crystal |
Jun, 2020
(5 years ago) | |
| US7285668 | TAKEDA | Process for the crystallization of (R)- or (S)-lansoprazole |
Jun, 2020
(5 years ago) | |
| US6664276 | TAKEDA | Benzimidazole compound crystal |
Jan, 2023
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7399485 | TAKEDA | Rapidly Disintegrable solid preparation |
May, 2018
(7 years ago) | |
|
US6238994 (Pediatric) | TAKEDA | Method of creating a rough electrode (high surface area) from Ti and TiN and resulting article |
Nov, 2019
(6 years ago) | |
|
US7399485 (Pediatric) | TAKEDA | Rapidly Disintegrable solid preparation |
Nov, 2018
(7 years ago) | |
|
US6939971 (Pediatric) | TAKEDA | Benzimidazole compound crystal |
Dec, 2020
(5 years ago) | |
|
US7285668 (Pediatric) | TAKEDA | Process for the crystallization of (R)- or (S)-lansoprazole |
Dec, 2020
(5 years ago) | |
| US6328994 | TAKEDA | Orally disintegrable tablets |
May, 2019
(6 years ago) | |
| US6939971 | TAKEDA | Benzimidazole compound crystal |
Jun, 2020
(5 years ago) | |
| US6238994 | TAKEDA | Method of creating a rough electrode (high surface area) from Ti and TiN and resulting article |
May, 2019
(6 years ago) | |
| US7875292 | TAKEDA | Orally disintegrable tablets |
May, 2019
(6 years ago) | |
| US7431942 | TAKEDA | Orally disintegrable tablets |
May, 2019
(6 years ago) | |
| US8784885 | TAKEDA | Controlled release preparation |
Oct, 2023
(2 years ago) | |
|
US6328994 (Pediatric) | TAKEDA | Orally disintegrable tablets |
Nov, 2019
(6 years ago) | |
|
US7875292 (Pediatric) | TAKEDA | Orally disintegrable tablets |
Nov, 2019
(6 years ago) | |
|
US7431942 (Pediatric) | TAKEDA | Orally disintegrable tablets |
Nov, 2019
(6 years ago) | |
|
US6462058 (Pediatric) | TAKEDA | Benzimidazole compound crystal |
Dec, 2020
(5 years ago) | |
|
US6664276 (Pediatric) | TAKEDA | Benzimidazole compound crystal |
Jul, 2023
(2 years ago) | |
| US9238029 | TAKEDA | Multiple PPI dosage form |
Jan, 2026
(21 days ago) | |
| US8461187 | TAKEDA | Multiple PPI dosage form |
Jan, 2026
(21 days ago) | |
| US9011926 | TAKEDA | Method for producing granules |
Feb, 2026
(16 days from now) | |
|
US8784885 (Pediatric) | TAKEDA | Controlled release preparation |
Apr, 2024
(1 year, 9 months ago) | |
| US9241910 | TAKEDA | Orally-disintegrating solid preparation |
Mar, 2029
(3 years from now) | |
| US8871273 | TAKEDA | Method for producing granules |
Jan, 2028
(1 year, 11 months from now) | |
|
US8461187 (Pediatric) | TAKEDA | Multiple PPI dosage form |
Jul, 2026
(5 months from now) | |
|
US8871273 (Pediatric) | TAKEDA | Method for producing granules |
Jul, 2028
(2 years from now) | |
Drugs and Companies using DEXLANSOPRAZOLE ingredient
Market Authorisation Date: 26 January, 2016
Treatment: Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks; Maintain healing of erosive esophagitis (ee) for up to 6 months
Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE
More Information on Dosage
DEXILANT SOLUTAB family patents
21. Duaklir Pressair patent expiration
DUAKLIR PRESSAIR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7078412 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(5 years ago) | |
| USRE46417 | COVIS | Quinuclidine derivatives and their use as muscarinic M3 receptor ligands |
Feb, 2025
(11 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10034867 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(5 years ago) | |
| US9333195 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(5 years ago) | |
| US10588895 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(5 years ago) | |
| US8129405 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(5 years ago) | |
| US9056100 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(5 years ago) | |
| US7750023 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(5 years ago) | |
| US6681768 | COVIS | Powder formulation disintegrating system and method for dry powder inhalers |
Aug, 2022
(3 years ago) | |
| US10085974 | COVIS | Dosage and formulation |
Mar, 2029
(3 years from now) | |
| US11000517 | COVIS | Dosage and formulation |
Mar, 2029
(3 years from now) | |
| US8051851 | COVIS | Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler |
Apr, 2027
(1 year, 2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Mar 29, 2022 |
Drugs and Companies using ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE ingredient
Market Authorisation Date: 29 March, 2019
Treatment: Maintenance treatment of chronic obstructive pulmonary disease (copd); Maintenance treatment of chronic pulmonary disease (copd)
Dosage: POWDER, METERED
More Information on Dosage
DUAKLIR PRESSAIR family patents
22. Duvyzat patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7329689 | ITALFARMACO | Monohydrate hydrochloride of the 4-hydroxycarbamoyl-phenyl)-carbamic acid (6-diethylaminomethyl-naphtalen-2-yl) ester |
Jan, 2026
(23 days ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9421184 | ITALFARMACO | Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dystrophy |
Feb, 2032
(5 years from now) | |
| US9867799 | ITALFARMACO | Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dystrophy |
Feb, 2032
(5 years from now) | |
| US10688047 | ITALFARMACO | Physically and chemically stable oral suspensions of givinostat |
Oct, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 21, 2029 |
| Orphan Drug Exclusivity(ODE-473) | Mar 21, 2031 |
Drugs and Companies using GIVINOSTAT HYDROCHLORIDE ingredient
NCE-1 date: 21 March, 2028
Market Authorisation Date: 21 March, 2024
Treatment: A method for the treatment of duchenne muscular dystrophy (dmd) using givinostat
Dosage: SUSPENSION
More Information on Dosage
DUVYZAT family patents
23. Edurant Ped patent expiration
EDURANT PED's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7125879 | JANSSEN | HIV inhibiting pyrimidines derivatives |
Apr, 2025
(9 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11065198 | JANSSEN | Dispersible compositions |
Oct, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 15, 2027 |
| Pediatric Exclusivity(PED) | Sep 15, 2027 |
Drugs and Companies using RILPIVIRINE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 March, 2024
Treatment: In combination with other antiretroviral agents for the treatment of hiv-1 infection in antiretroviral treatment-naive patients 2 years of age and older, weighing at least 14kg, with hiv-1 rna less th...
Dosage: TABLET, FOR SUSPENSION
More Information on Dosage
EDURANT PED family patents
24. Emend patent expiration
EMEND's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6096742 | MERCK | Polymorphic form of a tachykinin receptor antagonist |
Jul, 2018
(7 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8258132 | MERCK | Pharmaceutical composition of a tachykinin receptor antagonist |
Sep, 2027
(1 year, 7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2013 |
| M(M-82) | Mar 19, 2013 |
| New Dosing Schedule(D-128) | Nov 12, 2013 |
| New Patient Population(NPP) | Apr 03, 2021 |
| New Dosing Schedule(D-155) | Feb 01, 2019 |
| Pediatric Exclusivity(PED) | Oct 03, 2021 |
| New Dosing Schedule(D-186) | May 02, 2025 |
Drugs and Companies using APREPITANT ingredient
Market Authorisation Date: 17 December, 2015
Treatment: Prevention of nausea and vomiting associated with chemotherapy (cinv)
Dosage: FOR SUSPENSION
How can I launch a generic of EMEND before it's drug patent expiration?
More Information on Dosage
EMEND family patents
25. Epivir patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5905082 | VIIV | Crystalline oxathiolane derivatives |
May, 2016
(9 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6004968 | VIIV | Pharmaceutical compositions containing lamivudine |
Mar, 2018
(7 years ago) | |
|
US5905082 (Pediatric) | VIIV | Crystalline oxathiolane derivatives |
Nov, 2016
(9 years ago) | |
|
US6004968 (Pediatric) | VIIV | Pharmaceutical compositions containing lamivudine |
Sep, 2018
(7 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-147) | Mar 23, 2018 |
Drugs and Companies using LAMIVUDINE ingredient
Market Authorisation Date: 17 November, 1995
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
EPIVIR family patents
26. Flonase Sensimist Allergy Relief patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7101866 | HALEON | Anti-inflammatory androstane derivative |
Aug, 2021
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6858596 | HALEON | Formulation containing anti-inflammatory androstane derivative |
Aug, 2021
(4 years ago) | |
| US7541350 | HALEON | Formulation containing anti-inflammatory androstane derivative |
Aug, 2021
(4 years ago) | |
| US8752543 | HALEON | Fluid dispensing device |
Apr, 2026
(a month from now) | |
| US9320862 | HALEON | Fluid dispensing device |
Nov, 2024
(1 year, 3 months ago) | |
| US8347879 | HALEON | Fluid dispensing device |
Jul, 2028
(2 years from now) | |
| US8062264 | HALEON | Fluid dispensing device |
Apr, 2026
(a month from now) | |
| US8147461 | HALEON | Fluid dispensing device |
Oct, 2028
(2 years from now) | |
Drugs and Companies using FLUTICASONE FUROATE ingredient
Market Authorisation Date: 27 April, 2007
Treatment: Otc use: allergy symptom reliever; Temporarily relieves these symptoms due to hay fever or other upper respiratory allergies; Nasal congestion, runny nose, sneezing, itchy nose, and (itchy water eyes ...
Dosage: SPRAY, METERED
More Information on Dosage
FLONASE SENSIMIST ALLERGY RELIEF family patents
27. Forzinity patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7576061 | STEALTH BIOTHERAPS | NA |
Jan, 2026
(18 days ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12268724 | STEALTH BIOTHERAPS | NA |
Feb, 2034
(8 years from now) | |
| US11771734 | STEALTH BIOTHERAPS | NA |
Feb, 2034
(8 years from now) | |
| US11083772 | STEALTH BIOTHERAPS | NA |
Feb, 2034
(8 years from now) | |
| US11083771 | STEALTH BIOTHERAPS | NA |
Feb, 2034
(8 years from now) | |
| US9687519 | STEALTH BIOTHERAPS | NA |
Feb, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 19, 2030 |
Drugs and Companies using ELAMIPRETIDE HYDROCHLORIDE ingredient
NCE-1 date: 19 September, 2029
Market Authorisation Date: 19 September, 2025
Treatment: Method for treating barth syndrome in adult and pediatric patients weighing at least 30kg
Dosage: SOLUTION
More Information on Dosage
FORZINITY family patents
28. Gadavist patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5980864 | BAYER | 1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them |
Nov, 2021
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5980864 | BAYER | 1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them |
Nov, 2016
(9 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 14, 2016 |
| New Indication(I-688) | Jun 11, 2017 |
| New Indication(I-731) | Apr 27, 2019 |
| New Indication(I-801) | Jul 12, 2022 |
Drugs and Companies using GADOBUTROL ingredient
NCE-1 date: 15 March, 2015
Market Authorisation Date: 18 December, 2013
Treatment: Contrast agent for magnetic resonance imaging
Dosage: SOLUTION
More Information on Dosage
GADAVIST family patents
29. Gilenya patent expiration
GILENYA's oppositions filed in EPO
GILENYA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5604229 | NOVARTIS | 2-amino-1,3-propanediol compound and immunosuppressant |
Feb, 2019
(6 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6004565 | NOVARTIS | Compositions and methods of using compositions with accelerated lymphocyte homing immunosuppressive properties |
Sep, 2017
(8 years ago) | |
|
US5604229 (Pediatric) | NOVARTIS | 2-amino-1,3-propanediol compound and immunosuppressant |
Aug, 2019
(6 years ago) | |
| US5604229 | NOVARTIS | 2-amino-1,3-propanediol compound and immunosuppressant |
Feb, 2014
(11 years ago) | |
| US10543179 | NOVARTIS | Dosage regimen of an S1P receptor modulator |
Dec, 2027
(1 year, 10 months from now) | |
| US9592208 | NOVARTIS | Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol |
Mar, 2032
(6 years from now) | |
| US9187405 | NOVARTIS | S1P receptor modulators for treating relasping-remitting multiple sclerosis |
Jun, 2027
(1 year, 4 months from now) | |
| US8324283 | NOVARTIS | Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol |
Mar, 2026
(a month from now) | |
|
US8324283 (Pediatric) | NOVARTIS | Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol |
Sep, 2026
(7 months from now) | |
|
US9187405 (Pediatric) | NOVARTIS | S1P receptor modulators for treating relasping-remitting multiple sclerosis |
Dec, 2027
(1 year, 10 months from now) | |
|
US9592208 (Pediatric) | NOVARTIS | Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol |
Sep, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-106) | Jul 20, 2014 |
| New Chemical Entity Exclusivity(NCE) | Sep 21, 2015 |
| New Patient Population(NPP) | May 11, 2021 |
| New Strength(NS) | May 11, 2021 |
| Pediatric Exclusivity(PED) | Nov 11, 2021 |
Drugs and Companies using FINGOLIMOD HYDROCHLORIDE ingredient
NCE-1 date: 11 November, 2020
Market Authorisation Date: 11 May, 2018
Treatment: Treatment of autoimmune disease; Treatment of relapsing remitting multiple sclerosis by determining varicella zoster virus (vzv) status and vaccinating prior to commencing treatment; Treatment of mult...
Dosage: CAPSULE
How can I launch a generic of GILENYA before it's drug patent expiration?
More Information on Dosage
GILENYA family patents
30. Injectafer patent expiration
INJECTAFER's oppositions filed in EPO
INJECTAFER IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10519252 | AM REGENT | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct, 2023
(2 years ago) | |
| US11590097 | AM REGENT | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct, 2023
(2 years ago) | |
| US11291645 | AM REGENT | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct, 2023
(2 years ago) | |
| US11123321 | AM REGENT | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct, 2023
(2 years ago) | |
| US9376505 | AM REGENT | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct, 2023
(2 years ago) | |
| US7612109 | AM REGENT | Water-soluble iron-carbohydrate complexes, production thereof, and medicaments containing said complexes |
Feb, 2026
(2 days ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11478502 | AM REGENT | Methods and compositions for administration of iron |
Jan, 2027
(10 months from now) | |
| US11433091 | AM REGENT | Methods and compositions for administration of iron |
Jan, 2027
(10 months from now) | |
| US7754702 | AM REGENT | Methods and compositions for administration of iron |
Feb, 2028
(2 years from now) | |
| US8895612 | AM REGENT | Methods and compositions for administration of iron |
Jan, 2027
(10 months from now) | |
| US11364260 | AM REGENT | Methods and compositions for administration of iron |
Jan, 2027
(10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 25, 2016 |
| New Strength(NS) | Apr 28, 2024 |
| New Patient Population(NPP) | Nov 19, 2024 |
| New Indication(I-915) | May 31, 2026 |
Drugs and Companies using FERRIC CARBOXYMALTOSE ingredient
Market Authorisation Date: 28 April, 2021
Treatment: Method to treat iron deficiency anemia in adults with non-dialysis dependent chronic kidney disease & weighing at least 40 kg by intravenously administering ferric carboxymaltose to provide at least 0...
Dosage: SOLUTION
How can I launch a generic of INJECTAFER before it's drug patent expiration?
More Information on Dosage
INJECTAFER family patents
31. Iqirvo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7943661 | IPSEN | Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof |
Sep, 2024
(1 year, 4 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11857523 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| US11331292 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| US11185519 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| US12310935 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| US12295928 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| US12295927 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| US7632870 | IPSEN | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof |
Sep, 2024
(1 year, 4 months ago) | |
| US11850223 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| US12233038 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 10, 2029 |
| Orphan Drug Exclusivity(ODE-486) | Jun 10, 2031 |
Drugs and Companies using ELAFIBRANOR ingredient
NCE-1 date: 10 June, 2028
Market Authorisation Date: 10 June, 2024
Treatment: Treatment of primary biliary cholangitis (pbc) in combination with ursodeoxycholic acid (udca) in adults who have had an inadequate response to udca, or as monotherapy in patients unable to tolerate u...
Dosage: TABLET
More Information on Dosage
IQIRVO family patents
32. Iressa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5770599 | ASTRAZENECA | Quinazoline derivatives |
May, 2017
(8 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 13, 2018 |
| Orphan Drug Exclusivity(ODE) | Jul 13, 2022 |
| Orphan Drug Exclusivity(ODE-95) | Jul 13, 2022 |
Drugs and Companies using GEFITINIB ingredient
Market Authorisation Date: 13 July, 2015
Treatment: First-line treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutation...
Dosage: TABLET
More Information on Dosage
IRESSA family patents
33. Jadenu Sprinkle patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6465504 | NOVARTIS | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
Apr, 2019
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-239) | Dec 12, 2021 |
| M(M-241) | Jul 24, 2022 |
| M(M-263) | Jul 23, 2023 |
Drugs and Companies using DEFERASIROX ingredient
Market Authorisation Date: 18 May, 2017
Treatment: NA
Dosage: GRANULE
More Information on Dosage
JADENU SPRINKLE family patents
34. Jentadueto Xr patent expiration
JENTADUETO XR's oppositions filed in EPO
JENTADUETO XR IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7407955 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
May, 2025
(9 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8846695 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
Jun, 2030
(4 years from now) | |
| US6635280 | BOEHRINGER INGELHEIM | Extending the duration of drug release within the stomach during the fed mode |
Sep, 2016
(9 years ago) | |
| US6340475 | BOEHRINGER INGELHEIM | Extending the duration of drug release within the stomach during the fed mode |
Sep, 2016
(9 years ago) | |
| US7459428 | BOEHRINGER INGELHEIM | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(7 years ago) | |
| US6890898 | BOEHRINGER INGELHEIM | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(7 years ago) | |
| US8178541 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Aug, 2023
(2 years ago) | |
| US8119648 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Aug, 2023
(2 years ago) | |
| US6303661 | BOEHRINGER INGELHEIM | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
Apr, 2017
(8 years ago) | |
| US7078381 | BOEHRINGER INGELHEIM | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(7 years ago) | |
| US6488962 | BOEHRINGER INGELHEIM | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
Jun, 2020
(5 years ago) | |
| US10022379 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Apr, 2029
(3 years from now) | |
| US9555001 | BOEHRINGER INGELHEIM | Pharmaceutical composition and uses thereof |
Mar, 2033
(7 years from now) | |
|
US9555001 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition and uses thereof |
Sep, 2033
(7 years from now) | |
|
US10022379 (Pediatric) | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Oct, 2029
(3 years from now) | |
|
US9415016 (Pediatric) | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Oct, 2029
(3 years from now) | |
|
US9173859 (Pediatric) | BOEHRINGER INGELHEIM | Uses of DPP IV inhibitors |
Nov, 2027
(1 year, 8 months from now) | |
|
US7407955 (Pediatric) | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Nov, 2025
(3 months ago) | |
|
US8673927 (Pediatric) | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
Nov, 2027
(1 year, 8 months from now) | |
|
US9155705 (Pediatric) | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Nov, 2030
(4 years from now) | |
|
US8883805 (Pediatric) | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
May, 2026
(3 months from now) | |
| US8673927 | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
May, 2027
(1 year, 2 months from now) | |
|
US12364700 (Pediatric) | BOEHRINGER INGELHEIM | NA |
Dec, 2037
(11 years from now) | |
| US12364700 | BOEHRINGER INGELHEIM | NA |
Jun, 2037
(11 years from now) | |
| US9173859 | BOEHRINGER INGELHEIM | Uses of DPP IV inhibitors |
May, 2027
(1 year, 2 months from now) | |
| US11911388 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug |
Apr, 2030
(4 years from now) | |
| US9415016 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Apr, 2029
(3 years from now) | |
| US8883805 | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
Nov, 2025
(2 months ago) | |
| US9155705 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
May, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-258) | Jul 03, 2022 |
| M(M-252) | Mar 30, 2023 |
| M(M-295) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 27 May, 2016
Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin; Method of treating type 2 diabetes; Method of treating type 2 diabetes mellitus by administering...
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of JENTADUETO XR before it's drug patent expiration?
More Information on Dosage
JENTADUETO XR family patents
35. Juxtapid patent expiration
JUXTAPID's oppositions filed in EPO
JUXTAPID IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5712279 | CHIESI | Inhibitors of microsomal triglyceride transfer protein and method |
Feb, 2020
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5739135 | CHIESI | Inhibitors of microsomal triglyceride transfer protein and method |
Apr, 2015
(10 years ago) | |
| US6492365 | CHIESI | Microsomal triglyceride transfer protein |
Dec, 2019
(6 years ago) | |
| US5712279 | CHIESI | Inhibitors of microsomal triglyceride transfer protein and method |
Feb, 2015
(10 years ago) | |
| US7932268 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
Aug, 2027
(1 year, 6 months from now) | |
| US8618135 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
Mar, 2025
(11 months ago) | |
| US10016404 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
Mar, 2025
(11 months ago) | |
| US9433617 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
Mar, 2025
(11 months ago) | |
| US9265758 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
Mar, 2025
(11 months ago) | |
| US9364470 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
Mar, 2025
(11 months ago) | |
| US9861622 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
Mar, 2025
(11 months ago) | |
| US10555938 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
Mar, 2025
(11 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 21, 2017 |
| Orphan Drug Exclusivity(ODE) | Dec 21, 2019 |
| Orphan Drug Exclusivity(ODE-36) | Dec 21, 2019 |
Drugs and Companies using LOMITAPIDE MESYLATE ingredient
NCE-1 date: 21 December, 2016
Market Authorisation Date: 21 December, 2012
Treatment: Treatment of hypercholesterolemia, hyperlipidemia and hyperlipoproteinemia in patients with homozygous familial hypercholesterolemia; Treatment of hypercholesterolemia by decreasing the amount or acti...
Dosage: CAPSULE
More Information on Dosage
JUXTAPID family patents
36. Latuda patent expiration
LATUDA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5532372 | SUNOVION | Imide derivatives, and their production and use |
Jul, 2018
(7 years ago) | |
| USRE45573 | SUNOVION | Process for producing imide compound |
Jun, 2025
(7 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5532372 | SUNOVION | Imide derivatives, and their production and use |
Jul, 2018
(7 years ago) | |
| US9815827 | SUNOVION | Agent for treatment of schizophrenia |
Feb, 2024
(1 year, 11 months ago) | |
|
US5532372 (Pediatric) | SUNOVION | Imide derivatives, and their production and use |
Jan, 2019
(7 years ago) | |
| US9555027 | SUNOVION | Pharmaceutical composition |
May, 2026
(3 months from now) | |
| US9827242 | SUNOVION | Method of treatment for mental disorders |
May, 2031
(5 years from now) | |
| US9174975 | SUNOVION | Remedy for integration dysfunction syndrome |
Feb, 2024
(1 year, 11 months ago) | |
| US9259423 | SUNOVION | Method of treatment for mental disorders |
May, 2031
(5 years from now) | |
|
US9174975 (Pediatric) | SUNOVION | Remedy for integration dysfunction syndrome |
Aug, 2024
(1 year, 5 months ago) | |
| US8729085 | SUNOVION | Pharmaceutical composition |
May, 2026
(3 months from now) | |
| US9907794 | SUNOVION | Pharmaceutical composition |
May, 2026
(3 months from now) | |
| US8883794 | SUNOVION | Pharmaceutical composition |
May, 2026
(3 months from now) | |
|
US8729085 (Pediatric) | SUNOVION | Pharmaceutical composition |
Nov, 2026
(9 months from now) | |
|
US8883794 (Pediatric) | SUNOVION | Pharmaceutical composition |
Nov, 2026
(9 months from now) | |
|
US9907794 (Pediatric) | SUNOVION | Pharmaceutical composition |
Nov, 2026
(9 months from now) | |
|
US9259423 (Pediatric) | SUNOVION | Method of treatment for mental disorders |
Nov, 2031
(5 years from now) | |
|
USRE45573 (Pediatric) | SUNOVION | Process for producing imide compound |
Dec, 2025
(a month ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-134) | Apr 26, 2015 |
| New Chemical Entity Exclusivity(NCE) | Oct 28, 2015 |
| New Indication(I-674) | Jun 28, 2016 |
| M(M-195) | Jan 27, 2020 |
| Pediatric Exclusivity(PED) | Jul 27, 2020 |
| New Patient Population(NPP) | Mar 05, 2021 |
Drugs and Companies using LURASIDONE HYDROCHLORIDE ingredient
NCE-1 date: 28 July, 2019
Market Authorisation Date: 07 December, 2011
Treatment: Treatment of major depressive episodes associated with bipolar i disorder; Treatment of schizophrenia; Treatment of bipolar depression with improvement in attention function in bipolar disorder; Treat...
Dosage: TABLET
How can I launch a generic of LATUDA before it's drug patent expiration?
More Information on Dosage
LATUDA family patents
37. Lexiscan patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE47351 | ASTELLAS | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
Jun, 2019
(6 years ago) | |
| US8106183 | ASTELLAS | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
Feb, 2027
(11 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8536150 | ASTELLAS | Methods of myocardial perfusion imaging |
Jun, 2019
(6 years ago) | |
| US8470801 | ASTELLAS | Myocardial perfusion imaging methods and compositions |
Jun, 2019
(6 years ago) | |
| US8106029 | ASTELLAS | Use of A2A adenosine receptor agonists |
Jun, 2019
(6 years ago) | |
| US7655637 | ASTELLAS | N-pyrazole A2A receptor agonists |
Jun, 2019
(6 years ago) | |
| US7683037 | ASTELLAS | Myocardial perfusion imaging method |
Jun, 2019
(6 years ago) | |
| US7655636 | ASTELLAS | Use of A2A adenosine receptor agonists |
Jun, 2019
(6 years ago) | |
| US7582617 | ASTELLAS | Myocardial perfusion imaging method |
Jun, 2019
(6 years ago) | |
| US9289446 | ASTELLAS | Myocardial perfusion imaging methods and compositions |
Jun, 2019
(6 years ago) | |
| US7144872 | ASTELLAS | N-pyrazole A2A receptor agonists |
Jun, 2019
(6 years ago) | |
| US6642210 | ASTELLAS | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
Jun, 2019
(6 years ago) | |
| US9085601 | ASTELLAS | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
Feb, 2027
(11 months from now) | |
| US9045519 | ASTELLAS | N-pyrazole A2A receptor agonists |
Jun, 2019
(6 years ago) | |
| US8183226 | ASTELLAS | Myocardial perfusion imaging method |
Jun, 2019
(6 years ago) | |
| US7183264 | ASTELLAS | N-pyrazole A2A receptor agonists |
Jun, 2019
(6 years ago) | |
| US6403567 | ASTELLAS | N-pyrazole A2A adenosine receptor agonists |
Apr, 2022
(3 years ago) | |
| US8133879 | ASTELLAS | Myocardial perfusion imaging methods and compositions |
Jun, 2019
(6 years ago) | |
| USRE47301 | ASTELLAS | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
Feb, 2027
(11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 10, 2013 |
| M(M-194) | Jan 17, 2020 |
Drugs and Companies using REGADENOSON ingredient
NCE-1 date: 10 April, 2012
Market Authorisation Date: 10 April, 2008
Treatment: Method of myocardial imaging; Method for stimulating coronary vasodilation for purposes of imaging the heart; A method of myocardial perfusion imaging and increasing coronary blood flow; Method of pro...
Dosage: SOLUTION
How can I launch a generic of LEXISCAN before it's drug patent expiration?
More Information on Dosage
LEXISCAN family patents
38. Lumason patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5686060 | BRACCO | Stable microbubble suspensions comprising saturated phospholipids for ultrasound echography |
Nov, 2019
(6 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11723869 | BRACCO | Freeze-dried product and gas-filled microvesicles suspension |
May, 2039
(13 years from now) | |
| US10232061 | BRACCO | Freeze-dried formulation for gas-filled microvesicles |
Jul, 2038
(12 years from now) | |
| US10335502 | BRACCO | Freeze-dried formulation for gas-filled microvesicles |
Jul, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-728) | Mar 31, 2019 |
| New Chemical Entity Exclusivity(NCE) | Oct 10, 2019 |
| New Patient Population(NPP) | Nov 13, 2022 |
Drugs and Companies using SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES ingredient
NCE-1 date: 10 October, 2018
Market Authorisation Date: 15 October, 2014
Treatment: Use with ultrasound of the liver in adult and pediatric patients to characterize focal liver lesions
Dosage: FOR SUSPENSION
More Information on Dosage
LUMASON family patents
39. Lupkynis patent expiration
LUPKYNIS IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7332472 | AURINIA | Cyclosporine analogue mixtures and their use as immunomodulating agents |
Jan, 2026
(21 days ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11622991 | AURINIA | Protocol for treatment of lupus nephritis |
Dec, 2037
(11 years from now) | |
| US10286036 | AURINIA | Protocol for treatment of lupus nephritis |
Dec, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 22, 2026 |
Drugs and Companies using VOCLOSPORIN ingredient
NCE-1 date: 22 January, 2025
Market Authorisation Date: 22 January, 2021
Treatment: Treatment of patients with active lupus nephritis
Dosage: CAPSULE
More Information on Dosage
LUPKYNIS family patents
40. Lyrica Cr patent expiration
LYRICA CR's oppositions filed in EPO
LYRICA CR IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6197819 | UPJOHN | Gamma amino butyric acid analogs and optical isomers |
Dec, 2018
(7 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE41920 | UPJOHN | Isobutylgaba and its derivatives for the treatment of pain |
Dec, 2018
(7 years ago) | |
|
US6197819 (Pediatric) | UPJOHN | Gamma amino butyric acid analogs and optical isomers |
Jun, 2019
(6 years ago) | |
|
USRE41920 (Pediatric) | UPJOHN | Isobutylgaba and its derivatives for the treatment of pain |
Jun, 2019
(6 years ago) | |
| US10022447 | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
Nov, 2026
(8 months from now) | |
| US8945620 | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
Nov, 2026
(8 months from now) | |
| US9144559 | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
Nov, 2026
(8 months from now) | |
|
US9144559 (Pediatric) | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
May, 2027
(1 year, 2 months from now) | |
|
US10022447 (Pediatric) | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
May, 2027
(1 year, 2 months from now) | |
|
US8945620 (Pediatric) | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
May, 2027
(1 year, 2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 11, 2020 |
| Pediatric Exclusivity(PED) | Apr 11, 2021 |
Drugs and Companies using PREGABALIN ingredient
Market Authorisation Date: 11 October, 2017
Treatment: Treatment of postherpetic neuralgia; Treatment of neuropathic pain associated with diabetic peripheral neuropathy
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of LYRICA CR before it's drug patent expiration?
More Information on Dosage
LYRICA CR family patents
41. Macrilen patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6861409 | NOVO NORDISK | Growth hormone secretagogues |
Aug, 2022
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8192719 | NOVO NORDISK | Methods and kits to diagnose growth hormone deficiency by oral administration of EP 1572 or EP 1573 compounds |
Oct, 2027
(1 year, 8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 20, 2022 |
| Orphan Drug Exclusivity(ODE-170) | Dec 20, 2024 |
Drugs and Companies using MACIMORELIN ACETATE ingredient
NCE-1 date: 20 December, 2021
Market Authorisation Date: 20 December, 2017
Treatment: A method for the diagnosis of adult growth hormone deficiency by measuring the level of growth hormone after oral administration of macimorelin
Dosage: FOR SOLUTION
More Information on Dosage
MACRILEN family patents
42. Myrbetriq Granules patent expiration
MYRBETRIQ GRANULES IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7342117 | APGDI | α-form or β-form crystal of acetanilide derivative |
Nov, 2023
(2 years ago) | |
| US6346532 | APGDI | Amide derivatives or salts thereof |
Mar, 2022
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US10058536 (Pediatric) | APGDI | Pharmaceutical composition containing mirabegron |
Sep, 2036
(10 years from now) | |
|
US6346532 (Pediatric) | APGDI | Amide derivatives or salts thereof |
Sep, 2022
(3 years ago) | |
| US7982049 | APGDI | α-form or β-form crystal of acetanilide derivative |
Nov, 2023
(2 years ago) | |
| US10058536 | APGDI | Pharmaceutical composition containing mirabegron |
Mar, 2036
(10 years from now) | |
|
US7342117 (Pediatric) | APGDI | α-form or β-form crystal of acetanilide derivative |
May, 2024
(1 year, 9 months ago) | |
|
US7982049 (Pediatric) | APGDI | α-form or β-form crystal of acetanilide derivative |
May, 2024
(1 year, 9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 25, 2024 |
| Pediatric Exclusivity(PED) | Sep 25, 2024 |
Drugs and Companies using MIRABEGRON ingredient
Market Authorisation Date: 25 March, 2021
Treatment: Treatment of neurogenic detrusor overactivity (ndo) in pediatric patients aged 3 years and older by administration of an extended-release suspension formulation of mirabegron
Dosage: FOR SUSPENSION, EXTENDED RELEASE
More Information on Dosage
MYRBETRIQ GRANULES family patents
43. Nexium 24hr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7411070 | ASTRAZENECA | Form of S-omeprazole |
May, 2018
(7 years ago) | |
| US6369085 | ASTRAZENECA | Form of S-omeprazole |
May, 2018
(7 years ago) | |
| US5900424 | ASTRAZENECA | Omeprazole magnesium salt form |
May, 2016
(9 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6428810 (Pediatric) | ASTRAZENECA | Pharmaceutical formulation comprising omeprazole |
May, 2020
(5 years ago) | |
|
US7411070 (Pediatric) | ASTRAZENECA | Form of S-omeprazole |
Nov, 2018
(7 years ago) | |
|
US6369085 (Pediatric) | ASTRAZENECA | Form of S-omeprazole |
Nov, 2018
(7 years ago) | |
| US6428810 | ASTRAZENECA | Pharmaceutical formulation comprising omeprazole |
Nov, 2019
(6 years ago) | |
|
US5900424 (Pediatric) | ASTRAZENECA | Omeprazole magnesium salt form |
Nov, 2016
(9 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| RTO(RTO) | Mar 28, 2017 |
Drugs and Companies using ESOMEPRAZOLE MAGNESIUM ingredient
Market Authorisation Date: 23 November, 2015
Treatment: Method of treating frequent heartburn by administering an esomeprazole magnesium formulation as claimed; Method of treating frequent heartburn by administering an esomeprazole magnesium trihydrate as ...
Dosage: TABLET, DELAYED RELEASE
How can I launch a generic of NEXIUM 24HR before it's drug patent expiration?
More Information on Dosage
NEXIUM 24HR family patents
44. Norditropin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5849704 | NOVO NORDISK | Pharmaceutical formulation |
Dec, 2015
(10 years ago) | |
| US5633352 | NOVO NORDISK | Biosynthetic human growth hormone |
May, 2014
(11 years ago) | |
| US5849700 | NOVO NORDISK | Pharmaceutical formulation |
Dec, 2015
(10 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-572) | Oct 31, 2011 |
| Orphan Drug Exclusivity(ODE) | May 31, 2014 |
Drugs and Companies using SOMATROPIN RECOMBINANT ingredient
Market Authorisation Date: 23 January, 2015
Treatment: The long term treatment of growth failure due to lack of adequate endogenous growth hormone secretion in children
Dosage: INJECTABLE
More Information on Dosage
NORDITROPIN family patents
45. Norditropin Flexpro patent expiration
NORDITROPIN FLEXPRO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10376652 | NOVO NORDISK | Automatic injection device with a top release mechanism |
Jan, 2026
(18 days ago) | |
| US10357616 | NOVO NORDISK | Injection device with an end of dose feedback mechanism |
Jan, 2026
(18 days ago) | |
| US9457154 | NOVO NORDISK | Injection device with an end of dose feedback mechanism |
Sep, 2027
(1 year, 7 months from now) | |
| US7686786 | NOVO NORDISK | Dial-down mechanism for wind-up pen |
Aug, 2026
(5 months from now) | |
| US8841252 | NOVO NORDISK | Pharmaceutical formulation |
Dec, 2017
(8 years ago) | |
| US9108002 | NOVO NORDISK | Automatic injection device with a top release mechanism |
Jan, 2026
(18 days ago) | |
| US8684969 | NOVO NORDISK | Injection device with torsion spring and rotatable display |
Oct, 2025
(3 months ago) | |
| US9486588 | NOVO NORDISK | Automatic injection device with reset feature |
Jan, 2022
(4 years ago) | |
| US10220155 | NOVO NORDISK | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(5 months from now) | |
| US8672898 | NOVO NORDISK | Automatic injection device with reset feature |
Jan, 2022
(4 years ago) | |
| US8920383 | NOVO NORDISK | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(5 months from now) | |
| US6899699 | NOVO NORDISK | Automatic injection device with reset feature |
Jan, 2022
(4 years ago) | |
| US9861757 | NOVO NORDISK | Injection device with an end of dose feedback mechanism |
Jan, 2026
(18 days ago) | |
| US6716198 | NOVO NORDISK | Injection device |
Jun, 2021
(4 years ago) | |
| USRE46363 | NOVO NORDISK | Dial-down mechanism for wind-up pen |
Aug, 2026
(5 months from now) | |
| US9132239 | NOVO NORDISK | Dial-down mechanism for wind-up pen |
Feb, 2032
(5 years from now) | |
| US9775953 | NOVO NORDISK | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(5 months from now) | |
| US9616180 | NOVO NORDISK | Automatic injection device with a top release mechanism |
Jan, 2026
(18 days ago) | |
| US9687611 | NOVO NORDISK | Injection device with torsion spring and rotatable display |
Feb, 2027
(1 year, 19 days from now) | |
| US7762994 | NOVO NORDISK | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(1 year, 8 months ago) | |
| US8579869 | NOVO NORDISK | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(2 years ago) | |
| US5849704 | NOVO NORDISK | Pharmaceutical formulation |
Dec, 2015
(10 years ago) | |
| US5849700 | NOVO NORDISK | Pharmaceutical formulation |
Dec, 2015
(10 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-572) | Oct 31, 2011 |
| Orphan Drug Exclusivity(ODE) | May 31, 2014 |
Drugs and Companies using SOMATROPIN RECOMBINANT ingredient
Market Authorisation Date: 23 January, 2015
Treatment: Treatment of disorders responsive to growth hormone
Dosage: INJECTABLE
More Information on Dosage
NORDITROPIN FLEXPRO family patents
46. Norditropin Flexpro patent expiration
NORDITROPIN FLEXPRO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5849704 | NOVO NORDISK | Pharmaceutical formulation |
Dec, 2015
(10 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10376652 | NOVO NORDISK | Automatic injection device with a top release mechanism |
Jan, 2026
(18 days ago) | |
| US8684969 | NOVO NORDISK | Injection device with torsion spring and rotatable display |
Oct, 2025
(3 months ago) | |
| US8841252 | NOVO NORDISK | Pharmaceutical formulation |
Dec, 2017
(8 years ago) | |
| US5849700 | NOVO NORDISK | Pharmaceutical formulation |
Dec, 2015
(10 years ago) | |
| US7686786 | NOVO NORDISK | Dial-down mechanism for wind-up pen |
Aug, 2026
(5 months from now) | |
| US9486588 | NOVO NORDISK | Automatic injection device with reset feature |
Jan, 2022
(4 years ago) | |
| US9687611 | NOVO NORDISK | Injection device with torsion spring and rotatable display |
Feb, 2027
(1 year, 19 days from now) | |
| US6899699 | NOVO NORDISK | Automatic injection device with reset feature |
Jan, 2022
(4 years ago) | |
| US8672898 | NOVO NORDISK | Automatic injection device with reset feature |
Jan, 2022
(4 years ago) | |
| US8579869 | NOVO NORDISK | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(2 years ago) | |
| US7762994 | NOVO NORDISK | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(1 year, 8 months ago) | |
| US9861757 | NOVO NORDISK | Injection device with an end of dose feedback mechanism |
Jan, 2026
(18 days ago) | |
| US9616180 | NOVO NORDISK | Automatic injection device with a top release mechanism |
Jan, 2026
(18 days ago) | |
| USRE46363 | NOVO NORDISK | Dial-down mechanism for wind-up pen |
Aug, 2026
(5 months from now) | |
| US9132239 | NOVO NORDISK | Dial-down mechanism for wind-up pen |
Feb, 2032
(5 years from now) | |
| US9457154 | NOVO NORDISK | Injection device with an end of dose feedback mechanism |
Sep, 2027
(1 year, 7 months from now) | |
| US8920383 | NOVO NORDISK | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(5 months from now) | |
| US10357616 | NOVO NORDISK | Injection device with an end of dose feedback mechanism |
Jan, 2026
(18 days ago) | |
| US10220155 | NOVO NORDISK | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(5 months from now) | |
| US9775953 | NOVO NORDISK | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(5 months from now) | |
| US9108002 | NOVO NORDISK | Automatic injection device with a top release mechanism |
Jan, 2026
(18 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-572) | Oct 31, 2011 |
| Orphan Drug Exclusivity(ODE) | May 31, 2014 |
Drugs and Companies using SOMATROPIN ingredient
Market Authorisation Date: 23 January, 2015
Treatment: Treatment of disorders responsive to growth hormone
Dosage: INJECTABLE
More Information on Dosage
NORDITROPIN FLEXPRO family patents
47. Norditropin Nordiflex patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5849704 | NOVO NORDISK | Pharmaceutical formulation |
Dec, 2015
(10 years ago) | |
| US5849700 | NOVO NORDISK | Pharmaceutical formulation |
Dec, 2015
(10 years ago) | |
| US8841252 | NOVO NORDISK | Pharmaceutical formulation |
Dec, 2017
(8 years ago) | |
| USRE43834 | NOVO NORDISK | Injection syringe |
Jan, 2019
(7 years ago) | |
| USRE41956 | NOVO NORDISK | Dose setting limiter |
Jan, 2021
(5 years ago) | |
| US6235004 | NOVO NORDISK | Injection syringe |
Jan, 2019
(7 years ago) | |
| US6004297 | NOVO NORDISK | Injection syringe |
Jan, 2019
(7 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-572) | Oct 31, 2011 |
| Orphan Drug Exclusivity(ODE) | May 31, 2014 |
Drugs and Companies using SOMATROPIN RECOMBINANT ingredient
Market Authorisation Date: 23 January, 2015
Treatment: The long term treatment of growth failure due to lack of adequate endogenous growth hormone secretion in children
Dosage: INJECTABLE
More Information on Dosage
NORDITROPIN NORDIFLEX family patents
48. Nourianz patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7541363 | KYOWA KIRIN | Microcrystal |
Nov, 2024
(1 year, 2 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7727994 | KYOWA KIRIN | Methods of treating patients suffering from movement disorders |
Jan, 2023
(3 years ago) | |
| US7727993 | KYOWA KIRIN | Administering adenosine A2A receptor antagonist to reduce or suppress side effects of parkinson's disease therapy |
Jan, 2028
(1 year, 11 months from now) | |
| US8318201 | KYOWA KIRIN | Method of stabilizing diarylvinylene compound |
Sep, 2027
(1 year, 6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2024 |
Drugs and Companies using ISTRADEFYLLINE ingredient
NCE-1 date: 28 August, 2023
Market Authorisation Date: 27 August, 2019
Treatment: A method of reducing off time from l-dopa therapy, comprising administering, to a human patient with parkinson's disease, an effective amount of istradefylline, wherein the patient currently receives ...
Dosage: TABLET
More Information on Dosage
NOURIANZ family patents
49. Nuzyra patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7326696 | PARATEK | Amino-methyl substituted tetracycline compounds |
Sep, 2023
(2 years ago) | |
| US7553828 | PARATEK | 9-aminomethyl substituted minocycline compounds |
Jun, 2025
(8 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9365500 | PARATEK | 9-aminomethyl substituted minocycline compounds |
Jun, 2021
(4 years ago) | |
| US10383884 | PARATEK | 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) |
Oct, 2037
(11 years from now) | |
| US10124014 | PARATEK | Minocycline compounds and methods of use thereof |
Mar, 2029
(3 years from now) | |
| US10835542 | PARATEK | 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) |
Oct, 2037
(11 years from now) | |
| US9724358 | PARATEK | Minocycline compounds and methods of use thereof |
Mar, 2029
(3 years from now) | |
| US9265740 | PARATEK | Minocycline compounds and methods of use thereof |
Mar, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 02, 2023 |
| Generating Antibiotic Incentives Now(GAIN) | Oct 02, 2028 |
Drugs and Companies using OMADACYCLINE TOSYLATE ingredient
NCE-1 date: 03 October, 2027
Market Authorisation Date: 02 October, 2018
Treatment: Treatment of bacterial skin and skin structure infections; Treatment of community acquired bacterial pneumonia; Treatment of bacterial skin and skin structure infection
Dosage: POWDER
More Information on Dosage
NUZYRA family patents
50. Opsynvi patent expiration
OPSYNVI IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7094781 | ACTELION | Sulfamides and their use as endothelin receptor antagonists |
Dec, 2025
(2 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10946015 | ACTELION | Stable pharmaceutical compositions comprising a pyrimidine-sulfamide |
Sep, 2026
(7 months from now) | |
| US8268847 | ACTELION | Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor |
Apr, 2029
(3 years from now) | |
|
US7094781 (Pediatric) | ACTELION | NA |
Jun, 2026
(3 months from now) | |
|
US8268847 (Pediatric) | ACTELION | NA |
Oct, 2029
(3 years from now) | |
|
US10946015 (Pediatric) | ACTELION | NA |
Mar, 2027
(1 year, 1 month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 22, 2027 |
| Orphan Drug Exclusivity(ODE-475) | Mar 22, 2031 |
| Pediatric Exclusivity(PED) | Sep 22, 2031 |
Drugs and Companies using MACITENTAN; TADALAFIL ingredient
Market Authorisation Date: 22 March, 2024
Treatment: Use of the combination of macitentan and tadalafil for the chronic treatment of adults with pulmonary arterial hypertension; Method of treating pulmonary arterial hypertension comprising administering...
Dosage: TABLET
More Information on Dosage
OPSYNVI family patents
51. Oxycontin patent expiration
OXYCONTIN's oppositions filed in EPO
OXYCONTIN IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9073933 | PURDUE | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(10 months ago) | |
| US10407434 | PURDUE | Process for preparing oxycodone compositions |
Mar, 2025
(10 months ago) | |
| US9522919 | PURDUE | Oxycodone compositions |
Mar, 2025
(10 months ago) | |
| US10696684 | PURDUE | Process for preparing oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(10 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10130591 | PURDUE | Abuse-proofed dosage form |
Nov, 2023
(2 years ago) | |
| US8309060 | PURDUE | Abuse-proofed dosage form |
Nov, 2023
(2 years ago) | |
| US6488963 | PURDUE | Hot-melt extrudable pharmaceutical formulation |
Jun, 2017
(8 years ago) | |
| US7776314 | PURDUE | Abuse-proofed dosage system |
Apr, 2025
(9 months ago) | |
| US8337888 | PURDUE | Pharmaceutical formulation containing gelling agent |
Aug, 2022
(3 years ago) | |
| US7674800 | PURDUE | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(10 months ago) | |
| US7683072 | PURDUE | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
Mar, 2025
(10 months ago) | |
| US7674799 | PURDUE | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
Mar, 2025
(10 months ago) | |
| US8114383 | PURDUE | Abuse-proofed dosage form |
Oct, 2024
(1 year, 3 months ago) | |
| US9060976 | PURDUE | Pharmaceutical formulation containing gelling agent |
Aug, 2022
(3 years ago) | |
| US9675610 | PURDUE | Abuse-proofed dosage form |
Jun, 2023
(2 years ago) | |
| US5508042 | PURDUE | Controlled release oxycodone compositions |
Apr, 2013
(12 years ago) | |
| US10369109 | PURDUE | Abuse-proofed dosage form |
Jun, 2023
(2 years ago) | |
| US10675278 | PURDUE | Crush resistant delayed-release dosage forms |
Nov, 2023
(2 years ago) | |
| US8808741 | PURDUE | Tamper resistant dosage forms |
Aug, 2027
(1 year, 6 months from now) | |
| US9492393 | PURDUE | Tamper resistant dosage forms |
Aug, 2027
(1 year, 6 months from now) | |
| US9492391 | PURDUE | Tamper resistant dosage forms |
Aug, 2027
(1 year, 6 months from now) | |
| US12060361 | PURDUE | Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
Mar, 2025
(10 months ago) | |
| US9763933 | PURDUE | Tamper resistant dosage forms |
Aug, 2027
(1 year, 6 months from now) | |
| US9492392 | PURDUE | Tamper resistant dosage forms |
Aug, 2027
(1 year, 6 months from now) | |
| US12246094 | PURDUE | Tamper resistant dosage forms |
Aug, 2027
(1 year, 6 months from now) | |
| US9775808 | PURDUE | Tamper resistant dosage forms |
Aug, 2027
(1 year, 6 months from now) | |
| US9770416 | PURDUE | Tamper resistant dosage forms |
Aug, 2027
(1 year, 6 months from now) | |
| US8894987 | PURDUE | Tamper resistant dosage forms |
Mar, 2030
(4 years from now) | |
| US11964056 | PURDUE | Tamper resistant dosage forms |
Aug, 2027
(1 year, 6 months from now) | |
| US8894988 | PURDUE | Tamper resistant dosage forms |
Aug, 2027
(1 year, 6 months from now) | |
| US12280152 | PURDUE | Tamper resistant dosage forms |
Aug, 2027
(1 year, 6 months from now) | |
| US9492389 | PURDUE | Tamper resistant dosage forms |
Aug, 2027
(1 year, 6 months from now) | |
| US11304909 | PURDUE | Tamper resistant dosage forms |
Aug, 2027
(1 year, 6 months from now) | |
| US11304908 | PURDUE | Tamper resistant dosage forms |
Aug, 2027
(1 year, 6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-153) | Apr 16, 2016 |
| New Patient Population(NPP) | Aug 13, 2018 |
Drugs and Companies using OXYCODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 April, 2010
Treatment: Management of pain severe enough to require daily, around-the-clock, long term opioid treatment and for which alternative treatment options are inadequate; Management of moderate to severe pain when a...
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
OXYCONTIN family patents
52. Pepaxto patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6992207 | ONCOPEPTIDES | Melphalan derivatives and their use as cancer chemotherapeutic drugs |
Jun, 2024
(1 year, 7 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10543274 | ONCOPEPTIDES | Lyophilized preparation of cytotoxic dipeptides |
Apr, 2032
(6 years from now) | |
| US11344622 | ONCOPEPTIDES | Lyophilized preparation of cytotoxic dipeptides |
Apr, 2032
(6 years from now) | |
| US10285946 | ONCOPEPTIDES | Lyophilized preparations of melphalan flufenamide |
Apr, 2032
(6 years from now) | |
| US10869928 | ONCOPEPTIDES | Lyophilized preparation of cytotoxic dipeptides |
Apr, 2032
(6 years from now) | |
| US10322182 | ONCOPEPTIDES | Lyophilized preparation of cytotoxic dipeptides |
Apr, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 26, 2026 |
| Orphan Drug Exclusivity(ODE-348) | Feb 26, 2028 |
Drugs and Companies using MELPHALAN FLUFENAMIDE HYDROCHLORIDE ingredient
NCE-1 date: 26 February, 2025
Market Authorisation Date: 26 February, 2021
Treatment: In combination with dexamethasone to treat relapsed or refractory multiple myeloma (refactory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 anti-cd38 mab) in adults who received ...
Dosage: POWDER
More Information on Dosage
PEPAXTO family patents
53. Pradaxa patent expiration
PRADAXA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6087380 | BOEHRINGER INGELHEIM | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
Dec, 2021
(4 years ago) | |
| US7932273 | BOEHRINGER INGELHEIM | 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament |
Sep, 2025
(5 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7866474 (Pediatric) | BOEHRINGER INGELHEIM | Film container |
Mar, 2028
(2 years from now) | |
| US6087380 | BOEHRINGER INGELHEIM | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
Feb, 2018
(7 years ago) | |
| US9925174 | BOEHRINGER INGELHEIM | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof |
Jun, 2023
(2 years ago) | |
| US7866474 | BOEHRINGER INGELHEIM | Film container |
Aug, 2027
(1 year, 6 months from now) | |
|
US6087380 (Pediatric) | BOEHRINGER INGELHEIM | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
Jun, 2022
(3 years ago) | |
|
US9925174 (Pediatric) | BOEHRINGER INGELHEIM | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof |
Dec, 2023
(2 years ago) | |
| US9034822 | BOEHRINGER INGELHEIM | Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds |
Jan, 2031
(4 years from now) | |
|
US7932273 (Pediatric) | BOEHRINGER INGELHEIM | 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament |
Mar, 2026
(27 days from now) | |
|
US9034822 (Pediatric) | BOEHRINGER INGELHEIM | Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds |
Jul, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 19, 2015 |
| New Indication(I-682) | Apr 04, 2017 |
| New Indication(I-683) | Apr 04, 2017 |
| M(M-168) | Nov 20, 2018 |
| New Strength(NS) | Nov 20, 2018 |
| New Indication(I-862) | Jun 21, 2024 |
| New Product(NP) | Jun 21, 2024 |
| Pediatric Exclusivity(PED) | Dec 21, 2024 |
Drugs and Companies using DABIGATRAN ETEXILATE MESYLATE ingredient
Market Authorisation Date: 21 June, 2021
Treatment: Inhibition of thrombin; Method of reversing the anticoagulant effect of dabigatran using idarucizumab; Treatment of venous thrombotic disease
Dosage: PELLETS; CAPSULE
How can I launch a generic of PRADAXA before it's drug patent expiration?
More Information on Dosage
PRADAXA family patents
54. Promacta Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7160870 | NOVARTIS | Thrombopoietin mimetics |
Nov, 2022
(3 years ago) | |
| US6280959 | NOVARTIS | Metal complexes |
Oct, 2018
(7 years ago) | |
| US7473686 | NOVARTIS | Thrombopoietin mimetics |
May, 2021
(4 years ago) | |
| US7452874 | NOVARTIS | Thrombopoietin mimetics |
May, 2021
(4 years ago) | |
| US7547719 | NOVARTIS | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) |
Jul, 2025
(6 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7332481 | NOVARTIS | Thrombopoietin mimetics |
May, 2021
(4 years ago) | |
| US7790704 | NOVARTIS | Thrombopoietin mimetics |
May, 2021
(4 years ago) | |
| US7795293 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
May, 2023
(2 years ago) | |
|
US6280959 (Pediatric) | NOVARTIS | Metal complexes |
Apr, 2019
(6 years ago) | |
|
US7160870 (Pediatric) | NOVARTIS | Thrombopoietin mimetics |
May, 2023
(2 years ago) | |
|
US7795293 (Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Nov, 2023
(2 years ago) | |
|
US7452874 (Pediatric) | NOVARTIS | Thrombopoietin mimetics |
Nov, 2021
(4 years ago) | |
|
US7332481 (Pediatric) | NOVARTIS | Thrombopoietin mimetics |
Nov, 2021
(4 years ago) | |
|
US7473686 (Pediatric) | NOVARTIS | Thrombopoietin mimetics |
Nov, 2021
(4 years ago) | |
|
US7790704 (Pediatric) | NOVARTIS | Thrombopoietin mimetics |
Nov, 2021
(4 years ago) | |
|
US7547719 (Pediatric) | NOVARTIS | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) |
Jan, 2026
(25 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-149) | Jun 11, 2018 |
| New Indication(I-711) | Jun 11, 2018 |
| Orphan Drug Exclusivity(ODE) | Aug 26, 2021 |
| Orphan Drug Exclusivity(ODE-74) | Aug 26, 2021 |
| Pediatric Exclusivity(PED) | Feb 26, 2022 |
| ODE*(ODE*) | Nov 16, 2025 |
Drugs and Companies using ELTROMBOPAG OLAMINE ingredient
Market Authorisation Date: 27 September, 2018
Treatment: Treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy; Treatment of thrombocytopenia in adult and pediatric patients 1 ...
Dosage: FOR SUSPENSION
How can I launch a generic of PROMACTA KIT before it's drug patent expiration?
More Information on Dosage
PROMACTA KIT family patents
55. Rytelo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7494982 | GERON | Modified oligonucleotides for telomerase inhibition |
Dec, 2025
(a month ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12442000 | GERON | NA |
Mar, 2033
(7 years from now) | |
| US9375485 | GERON | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
Mar, 2033
(7 years from now) | |
| US9388416 | GERON | Modified oligonucleotides for telomerase inhibition |
Sep, 2026
(6 months from now) | |
| US9388415 | GERON | Modified oligonucleotides for telomerase inhibition |
Sep, 2026
(6 months from now) | |
| US12171778 | GERON | Methods of treating myelodysplastic syndrome |
Jun, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-482) | Jun 06, 2031 |
Drugs and Companies using IMETELSTAT SODIUM ingredient
Market Authorisation Date: 06 June, 2024
Treatment: Treatment of patients with myelodysplastic syndromes (mds) with transfusion-dependent anemia
Dosage: POWDER
More Information on Dosage
RYTELO family patents
56. Saxenda patent expiration
SAXENDA's oppositions filed in EPO
SAXENDA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6458924 | NOVO NORDISK | Derivatives of GLP-1 analogs |
Aug, 2017
(8 years ago) | |
| US6268343 | NOVO NORDISK | Derivatives of GLP-1 analogs |
Aug, 2022
(3 years ago) | |
| US7235627 | NOVO NORDISK | Derivatives of GLP-1 analogs |
Aug, 2017
(8 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6899699 | NOVO NORDISK | Automatic injection device with reset feature |
Jan, 2022
(4 years ago) | |
| US7686786 | NOVO NORDISK | Dial-down mechanism for wind-up pen |
Aug, 2026
(5 months from now) | |
| US8579869 | NOVO NORDISK | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(2 years ago) | |
|
US6268343 (Pediatric) | NOVO NORDISK | Derivatives of GLP-1 analogs |
Feb, 2023
(2 years ago) | |
|
US8579869 (Pediatric) | NOVO NORDISK | Needle mounting system and a method for mounting a needle assembly |
Dec, 2023
(2 years ago) | |
| US9486588 | NOVO NORDISK | Automatic injection device with reset feature |
Jan, 2022
(4 years ago) | |
| US8846618 | NOVO NORDISK | Stable formulation of modified GLP-1 |
Jun, 2022
(3 years ago) | |
| US8672898 | NOVO NORDISK | Automatic injection device with reset feature |
Jan, 2022
(4 years ago) | |
|
US8846618 (Pediatric) | NOVO NORDISK | Stable formulation of modified GLP-1 |
Dec, 2022
(3 years ago) | |
|
US9486588 (Pediatric) | NOVO NORDISK | Automatic injection device with reset feature |
Jul, 2022
(3 years ago) | |
|
US8672898 (Pediatric) | NOVO NORDISK | Automatic injection device with reset feature |
Jul, 2022
(3 years ago) | |
|
US6899699 (Pediatric) | NOVO NORDISK | Automatic injection device with reset feature |
Jul, 2022
(3 years ago) | |
| US9968659 | NOVO NORDISK | Liraglutide in cardiovascular conditions |
Jan, 2037
(10 years from now) | |
| US7762994 | NOVO NORDISK | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(1 year, 8 months ago) | |
| US10220155 | NOVO NORDISK | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(5 months from now) | |
| US9861757 | NOVO NORDISK | Injection device with an end of dose feedback mechanism |
Jan, 2026
(18 days ago) | |
| US11097063 | NOVO NORDISK | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(5 months from now) | |
| US9616180 | NOVO NORDISK | Automatic injection device with a top release mechanism |
Jan, 2026
(18 days ago) | |
| US9687611 | NOVO NORDISK | Injection device with torsion spring and rotatable display |
Feb, 2027
(1 year, 19 days from now) | |
| US9457154 | NOVO NORDISK | Injection device with an end of dose feedback mechanism |
Sep, 2027
(1 year, 7 months from now) | |
| US11311679 | NOVO NORDISK | Automatic injection device with a top release mechanism |
Jan, 2026
(18 days ago) | |
| US8684969 | NOVO NORDISK | Injection device with torsion spring and rotatable display |
Oct, 2025
(3 months ago) | |
| US9775953 | NOVO NORDISK | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(5 months from now) | |
| US8920383 | NOVO NORDISK | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(5 months from now) | |
| US10357616 | NOVO NORDISK | Injection device with an end of dose feedback mechanism |
Jan, 2026
(18 days ago) | |
|
US7762994 (Pediatric) | NOVO NORDISK | Needle mounting system and a method for mounting a needle assembly |
Nov, 2024
(1 year, 2 months ago) | |
| US10376652 | NOVO NORDISK | Automatic injection device with a top release mechanism |
Jan, 2026
(18 days ago) | |
| US9132239 | NOVO NORDISK | Dial-down mechanism for wind-up pen |
Feb, 2032
(5 years from now) | |
| US11446443 | NOVO NORDISK | Injection device with torsion spring and rotatable display |
Oct, 2025
(3 months ago) | |
| US9108002 | NOVO NORDISK | Automatic injection device with a top release mechanism |
Jan, 2026
(12 days ago) | |
| US8114833 | NOVO NORDISK | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Aug, 2025
(5 months ago) | |
|
US8920383 (Pediatric) | NOVO NORDISK | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jan, 2027
(11 months from now) | |
|
USRE46363 (Pediatric) | NOVO NORDISK | Dial-down mechanism for wind-up pen |
Feb, 2027
(11 months from now) | |
|
US9457154 (Pediatric) | NOVO NORDISK | Injection device with an end of dose feedback mechanism |
Mar, 2028
(2 years from now) | |
|
US9687611 (Pediatric) | NOVO NORDISK | Injection device with torsion spring and rotatable display |
Aug, 2027
(1 year, 6 months from now) | |
|
US9861757 (Pediatric) | NOVO NORDISK | Injection device with an end of dose feedback mechanism |
Jul, 2026
(5 months from now) | |
|
US9616180 (Pediatric) | NOVO NORDISK | Automatic injection device with a top release mechanism |
Jul, 2026
(5 months from now) | |
|
US9775953 (Pediatric) | NOVO NORDISK | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jan, 2027
(11 months from now) | |
|
US9108002 (Pediatric) | NOVO NORDISK | Automatic injection device with a top release mechanism |
Jul, 2026
(5 months from now) | |
|
US9132239 (Pediatric) | NOVO NORDISK | Dial-down mechanism for wind-up pen |
Aug, 2032
(6 years from now) | |
|
US8684969 (Pediatric) | NOVO NORDISK | Injection device with torsion spring and rotatable display |
Apr, 2026
(2 months from now) | |
|
US10220155 (Pediatric) | NOVO NORDISK | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jan, 2027
(11 months from now) | |
| USRE46363 | NOVO NORDISK | Dial-down mechanism for wind-up pen |
Aug, 2026
(5 months from now) | |
|
US8114833 (Pediatric) | NOVO NORDISK | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Feb, 2026
(5 days from now) | |
|
US9968659 (Pediatric) | NOVO NORDISK | Liraglutide in cardiovascular conditions |
Jul, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2015 |
| New Product(NP) | Jan 25, 2017 |
| New Patient Population(NPP) | Dec 04, 2023 |
Drugs and Companies using LIRAGLUTIDE ingredient
NCE-1 date: 25 January, 2014
Market Authorisation Date: 23 December, 2014
Treatment: Cardiovascular outcomes trial of liraglutide 1.8 mg in patients with type 2 diabetes and cardiovascular disease; Method for chronic weight management by treating obesity
Dosage: SOLUTION
How can I launch a generic of SAXENDA before it's drug patent expiration?
More Information on Dosage
SAXENDA family patents
57. Selzentry patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6667314 | VIIV | Tropane derivatives useful in therapy |
Aug, 2021
(4 years ago) | |
| US6586430 | VIIV | CCR5 modulators |
Dec, 2019
(6 years ago) | |
| US7576097 | VIIV | Tropane derivatives useful in therapy |
May, 2021
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6667314 | VIIV | Tropane derivatives useful in therapy |
Aug, 2021
(4 years ago) | |
|
US7576097 (Pediatric) | VIIV | Tropane derivatives useful in therapy |
Nov, 2021
(4 years ago) | |
|
US7368460 (Pediatric) | VIIV | Tropane derivatives useful in therapy |
May, 2023
(2 years ago) | |
| US6586430 | VIIV | CCR5 modulators |
Dec, 2019
(6 years ago) | |
| US7368460 | VIIV | Tropane derivatives useful in therapy |
Nov, 2022
(3 years ago) | |
| US7576097 | VIIV | Tropane derivatives useful in therapy |
May, 2021
(4 years ago) | |
|
US6667314 (Pediatric) | VIIV | Tropane derivatives useful in therapy |
Feb, 2022
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 06, 2012 |
| New Patient Population(NPP) | Oct 30, 2023 |
| New Product(NP) | Nov 04, 2019 |
| New Strength(NS) | Nov 04, 2019 |
| Pediatric Exclusivity(PED) | Apr 30, 2024 |
Drugs and Companies using MARAVIROC ingredient
NCE-1 date: 07 August, 2011
Market Authorisation Date: 04 November, 2016
Treatment: Method of treating patients infected with ccr5-tropic hiv-1
Dosage: TABLET; SOLUTION
How can I launch a generic of SELZENTRY before it's drug patent expiration?
More Information on Dosage
SELZENTRY family patents
58. Soliqua 100/33 patent expiration
SOLIQUA 100/33 IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE45313 | SANOFI | Exendin variant peptides |
Jul, 2020
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9950039 | SANOFI | Insulin glargine/lixisenatide fixed ratio formulation |
Dec, 2035
(9 years from now) | |
| US9827379 | SANOFI | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(1 year, 11 months ago) | |
| US9775954 | SANOFI | Pen-type injector |
Mar, 2024
(1 year, 11 months ago) | |
| US8992486 | SANOFI | Pen-type injector |
Jun, 2024
(1 year, 8 months ago) | |
| US9011391 | SANOFI | Pen-type injector |
Mar, 2024
(1 year, 10 months ago) | |
| US9821032 | SANOFI | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
May, 2032
(6 years from now) | |
| US10029011 | SANOFI | Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine |
Nov, 2030
(4 years from now) | |
| US9561331 | SANOFI | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(1 year, 5 months ago) | |
| US9604009 | SANOFI | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(1 year, 5 months ago) | |
| US9707176 | SANOFI | Pharmaceutical composition comprising a GLP-1 agonist and methionine |
Nov, 2030
(4 years from now) | |
| US9604008 | SANOFI | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(1 year, 11 months ago) | |
| US9408979 | SANOFI | Pen-type injector |
Mar, 2024
(1 year, 11 months ago) | |
| US7918833 | SANOFI | Pen-type injector |
Sep, 2027
(1 year, 7 months from now) | |
| US10117909 | SANOFI | Combination of an insulin and a GLP-1 agonist |
Oct, 2029
(3 years from now) | |
| US9233211 | SANOFI | Relating to a pen-type injector |
Mar, 2024
(1 year, 11 months ago) | |
| US8679069 | SANOFI | Pen-type injector |
Apr, 2025
(9 months ago) | |
| US9526844 | SANOFI | Pen-type injector |
Mar, 2024
(1 year, 11 months ago) | |
| US8603044 | SANOFI | Pen-type injector |
Mar, 2024
(1 year, 11 months ago) | |
| US9533105 | SANOFI | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(1 year, 5 months ago) | |
| US9717852 | SANOFI | Cartridge holder and pen-type injector |
Apr, 2033
(7 years from now) | |
| US9526764 | SANOFI | Combination of an insulin and a GLP-1-agonist |
Oct, 2029
(3 years from now) | |
| US8512297 | SANOFI | Pen-type injector |
Sep, 2024
(1 year, 4 months ago) | |
| US8556864 | SANOFI | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(1 year, 11 months ago) | |
| US9623189 | SANOFI | Relating to drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(1 year, 5 months ago) | |
| US9610409 | SANOFI | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(1 year, 11 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Nov 21, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jul 27, 2021 |
Drugs and Companies using INSULIN GLARGINE; LIXISENATIDE ingredient
NCE-1 date: 27 July, 2020
Market Authorisation Date: 21 November, 2016
Treatment: Improvement in glycemic control in adults with type 2 diabetes mellitus inadequately controlled by lixisenatide in combination with metformin and a second oral antidiabetic drug; Improvement in glycem...
Dosage: SOLUTION
More Information on Dosage
SOLIQUA 100/33 family patents
59. Spiriva Respimat patent expiration
SPIRIVA RESPIMAT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE39820 | BOEHRINGER INGELHEIM | Esters of thienyl carboxylic acids and amino alcohols and their quaternization products |
Jan, 2018
(8 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6149054 (Pediatric) | BOEHRINGER INGELHEIM | Mechanical counter for a metering apparatus |
Jun, 2017
(8 years ago) | |
| US7246615 | BOEHRINGER INGELHEIM | Atomising nozzle and filter and spray generating device |
May, 2016
(9 years ago) | |
| US7988001 | BOEHRINGER INGELHEIM | Container provided with a pressure equalization opening |
Aug, 2021
(4 years ago) | |
| US7104470 | BOEHRINGER INGELHEIM | Device for producing high pressure in a fluid in miniature |
Oct, 2016
(9 years ago) | |
| US6453795 | BOEHRINGER INGELHEIM | Locking mechanism for a spring-actuated device |
Dec, 2016
(9 years ago) | |
| US6176242 | BOEHRINGER INGELHEIM | Method of treating manic depression by brain infusion |
May, 2016
(9 years ago) | |
|
USRE39820 (Pediatric) | BOEHRINGER INGELHEIM | Esters of thienyl carboxylic acids and amino alcohols and their quaternization products |
Jul, 2018
(7 years ago) | |
| US5964416 | BOEHRINGER INGELHEIM | Device for producing high pressure in a fluid in miniature |
Oct, 2016
(9 years ago) | |
| US6726124 | BOEHRINGER INGELHEIM | Device for producing high pressure in a fluid in miniature |
Oct, 2016
(9 years ago) | |
| US6988496 | BOEHRINGER INGELHEIM | Cartridge for a liquid |
Feb, 2020
(5 years ago) | |
| US6977042 | BOEHRINGER INGELHEIM | Microstructured filter |
Aug, 2018
(7 years ago) | |
|
US6988496 (Pediatric) | BOEHRINGER INGELHEIM | Cartridge for a liquid |
Aug, 2020
(5 years ago) | |
| US6176442 | BOEHRINGER INGELHEIM | Device for mounting a component exposed to a pressurized fluid |
May, 2016
(9 years ago) | |
| US6149054 | BOEHRINGER INGELHEIM | Mechanical counter for a metering apparatus |
Dec, 2016
(9 years ago) | |
|
US6846413 (Pediatric) | BOEHRINGER INGELHEIM | Microstructured filter |
Feb, 2019
(6 years ago) | |
| US6846413 | BOEHRINGER INGELHEIM | Microstructured filter |
Aug, 2018
(7 years ago) | |
|
US5964416 (Pediatric) | BOEHRINGER INGELHEIM | Device for producing high pressure in a fluid in miniature |
Apr, 2017
(8 years ago) | |
|
US6453795 (Pediatric) | BOEHRINGER INGELHEIM | Locking mechanism for a spring-actuated device |
Jun, 2017
(8 years ago) | |
|
US7104470 (Pediatric) | BOEHRINGER INGELHEIM | Device for producing high pressure in a fluid in miniature |
Apr, 2017
(8 years ago) | |
|
US6726124 (Pediatric) | BOEHRINGER INGELHEIM | Device for producing high pressure in a fluid in miniature |
Apr, 2017
(8 years ago) | |
|
US7246615 (Pediatric) | BOEHRINGER INGELHEIM | Atomising nozzle and filter and spray generating device |
Dec, 2016
(9 years ago) | |
|
US6176442 (Pediatric) | BOEHRINGER INGELHEIM | Device for mounting a component exposed to a pressurized fluid |
Dec, 2016
(9 years ago) | |
| US7802568 | BOEHRINGER INGELHEIM | Cartridge for a liquid |
Feb, 2019
(6 years ago) | |
|
US7802568 (Pediatric) | BOEHRINGER INGELHEIM | Cartridge for a liquid |
Aug, 2019
(6 years ago) | |
|
US6977042 (Pediatric) | BOEHRINGER INGELHEIM | Microstructured filter |
Feb, 2019
(6 years ago) | |
|
US7988001 (Pediatric) | BOEHRINGER INGELHEIM | Container provided with a pressure equalization opening |
Feb, 2022
(4 years ago) | |
| US7896264 | BOEHRINGER INGELHEIM | Microstructured high pressure nozzle with built-in filter function |
May, 2025
(8 months ago) | |
| US7396341 | BOEHRINGER INGELHEIM | Blocking device for a locking stressing mechanism having a spring-actuated output drive device |
Oct, 2026
(8 months from now) | |
| US7837235 | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Mar, 2028
(2 years from now) | |
| US8733341 | BOEHRINGER INGELHEIM | Atomizer and method of atomizing fluid with a nozzle rinsing mechanism |
Oct, 2030
(4 years from now) | |
| US9027967 | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Mar, 2027
(1 year, 1 month from now) | |
|
US7396341 (Pediatric) | BOEHRINGER INGELHEIM | Blocking device for a locking stressing mechanism having a spring-actuated output drive device |
Apr, 2027
(1 year, 2 months from now) | |
|
US8733341 (Pediatric) | BOEHRINGER INGELHEIM | Atomizer and method of atomizing fluid with a nozzle rinsing mechanism |
Apr, 2031
(5 years from now) | |
|
US9027967 (Pediatric) | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Sep, 2027
(1 year, 7 months from now) | |
|
US7896264 (Pediatric) | BOEHRINGER INGELHEIM | Microstructured high pressure nozzle with built-in filter function |
Nov, 2025
(2 months ago) | |
| US7284474 | BOEHRINGER INGELHEIM | Piston-pumping system having o-ring seal properties |
Aug, 2024
(1 year, 5 months ago) | |
|
US7837235 (Pediatric) | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Sep, 2028
(2 years from now) | |
|
US7284474 (Pediatric) | BOEHRINGER INGELHEIM | Piston-pumping system having o-ring seal properties |
Feb, 2025
(11 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 15, 2018 |
| New Patient Population(NPP) | Feb 15, 2020 |
| Pediatric Exclusivity(PED) | Aug 15, 2020 |
Drugs and Companies using TIOTROPIUM BROMIDE ingredient
Market Authorisation Date: 15 September, 2015
Treatment: NA
Dosage: SPRAY, METERED
How can I launch a generic of SPIRIVA RESPIMAT before it's drug patent expiration?
More Information on Dosage
SPIRIVA RESPIMAT family patents
60. Targiniq patent expiration
TARGINIQ's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7674800 | PURDUE | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(10 months ago) | |
| US7683072 | PURDUE | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
Mar, 2025
(10 months ago) | |
| US9522919 | PURDUE | Oxycodone compositions |
Mar, 2025
(10 months ago) | |
| US9073933 | PURDUE | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(10 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8673355 | PURDUE | Opioid agonist/antagonist combinations |
Dec, 2018
(7 years ago) | |
| US7674799 | PURDUE | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
Mar, 2025
(10 months ago) | |
| US8822487 | PURDUE | Opioid agonist/opioid antagonist/acetaminophen combinations |
Dec, 2018
(7 years ago) | |
| US9907793 | PURDUE | Pharmaceutical preparation containing oxycodone and naloxone |
Apr, 2023
(2 years ago) | |
| US9283216 | PURDUE | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(3 years ago) | |
| US6696066 | PURDUE | Opioid agonist/antagonist combinations |
Dec, 2018
(7 years ago) | |
| US9161937 | PURDUE | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(3 years ago) | |
| US9511066 | PURDUE | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(3 years ago) | |
| US9555000 | PURDUE | Pharmaceutical preparation containing oxycodone and naloxone |
Apr, 2023
(2 years ago) | |
| US8969369 | PURDUE | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(3 years ago) | |
| US9056051 | PURDUE | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(3 years ago) | |
| US9205082 | PURDUE | Opioid agonist/antagonist combinations |
Dec, 2018
(7 years ago) | |
| US9283221 | PURDUE | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(3 years ago) | |
| US9474750 | PURDUE | Opioid agonist/opioid antagonist/acetaminophen combinations |
Dec, 2018
(7 years ago) | |
| US9168252 | PURDUE | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(3 years ago) | |
| US6277384 | PURDUE | Opioid agonist/antagonist combinations |
Dec, 2018
(7 years ago) | |
| US9084729 | PURDUE | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(3 years ago) | |
| US9345701 | PURDUE | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(3 years ago) | |
| US8846091 | PURDUE | Matrix for sustained, invariant and independent release of active compounds |
Apr, 2023
(2 years ago) | |
| US8846090 | PURDUE | Matrix for sustained, invariant and independent release of active compounds |
Apr, 2023
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jul 23, 2017 |
Drugs and Companies using NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 23 July, 2014
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate; Management of pain severe enough to require ...
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
TARGINIQ family patents
61. Tpoxx patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8124643 | SIGA | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Jun, 2024
(1 year, 7 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8530509 | SIGA | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Jun, 2024
(1 year, 7 months ago) | |
| US9907859 | SIGA | ST-246 liquid formulations and methods |
Aug, 2031
(5 years from now) | |
| US10576165 | SIGA | ST-246 liquid formulations and methods |
Aug, 2031
(5 years from now) | |
| US8802714 | SIGA | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Jun, 2024
(1 year, 7 months ago) | |
| US7737168 | SIGA | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Sep, 2031
(5 years from now) | |
| US8039504 | SIGA | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Jul, 2027
(1 year, 5 months from now) | |
| US9233097 | SIGA | ST-246 liquid formulations |
Aug, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 13, 2023 |
| Orphan Drug Exclusivity(ODE-200) | Jul 13, 2025 |
Drugs and Companies using TECOVIRIMAT ingredient
NCE-1 date: 13 July, 2022
Market Authorisation Date: 18 May, 2022
Treatment: Tpoxx is indicated for the treatment of human smallpox disease in adults and pediatric patients weighing at least 3 kg
Dosage: SOLUTION
More Information on Dosage
TPOXX family patents
62. Truvada patent expiration
TRUVADA's oppositions filed in EPO
TRUVADA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5922695 | GILEAD | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jul, 2017
(8 years ago) | |
| US5935946 | GILEAD | Nucleotide analog composition and synthesis method |
Jul, 2017
(8 years ago) | |
| US5977089 | GILEAD | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul, 2017
(8 years ago) | |
| US5814639 | GILEAD | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Sep, 2015
(10 years ago) | |
| US5914331 | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jul, 2017
(8 years ago) | |
| US6703396 | GILEAD | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Mar, 2021
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5814639 (Pediatric) | GILEAD | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Mar, 2016
(9 years ago) | |
| US5977089 | GILEAD | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul, 2017
(8 years ago) | |
| US6043230 | GILEAD | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul, 2017
(8 years ago) | |
| US6642245 | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Nov, 2020
(5 years ago) | |
|
US5922695 (Pediatric) | GILEAD | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jan, 2018
(8 years ago) | |
|
US5935946 (Pediatric) | GILEAD | Nucleotide analog composition and synthesis method |
Jan, 2018
(8 years ago) | |
|
US5914331 (Pediatric) | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jan, 2018
(8 years ago) | |
|
US5977089 (Pediatric) | GILEAD | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan, 2018
(8 years ago) | |
|
US6043230 (Pediatric) | GILEAD | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan, 2018
(8 years ago) | |
|
US8716264 (Pediatric) | GILEAD | Compositions and methods for combination antiviral therapy |
Jul, 2024
(1 year, 6 months ago) | |
| US5814639 | GILEAD | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Sep, 2015
(10 years ago) | |
| US5922695 | GILEAD | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jul, 2017
(8 years ago) | |
| US5935946 | GILEAD | Nucleotide analog composition and synthesis method |
Jul, 2017
(8 years ago) | |
|
US6642245 (Pediatric) | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
May, 2021
(4 years ago) | |
|
US6703396 (Pediatric) | GILEAD | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Sep, 2021
(4 years ago) | |
| US5914331 | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jul, 2017
(8 years ago) | |
| US8592397 | GILEAD | Compositions and methods for combination antiviral therapy |
Jan, 2024
(2 years ago) | |
| US9744181 | GILEAD | Compositions and methods for combination antiviral therapy |
Jan, 2024
(2 years ago) | |
| US6703396 | GILEAD | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Mar, 2021
(4 years ago) | |
| US9457036 | GILEAD | Compositions and methods for combination antiviral therapy |
Jan, 2024
(2 years ago) | |
| US8716264 | GILEAD | Compositions and methods for combination antiviral therapy |
Jan, 2024
(2 years ago) | |
Drugs and Companies using EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient
Market Authorisation Date: 10 March, 2016
Treatment: Treatment of hiv-1 infection in pediatric patients 12 years of age and older; Method of treatment of adults infected with hiv-1; Treatment of hiv; Treatment of hiv infection; Prophylaxis of hiv-1 infe...
Dosage: TABLET
How can I launch a generic of TRUVADA before it's drug patent expiration?
More Information on Dosage
TRUVADA family patents
63. Tudorza Pressair patent expiration
TUDORZA PRESSAIR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE46417 | COVIS | Quinuclidine derivatives and their use as muscarinic M3 receptor ligands |
Feb, 2025
(11 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10034867 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(5 years ago) | |
| US9056100 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(5 years ago) | |
| US9333195 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(5 years ago) | |
| US5840279 | COVIS | Pharmaceutical powder cartridge with integrated metering device and inhaler for powdered medicaments |
Jun, 2016
(9 years ago) | |
| US6750226 | COVIS | Quinuclidine derivatives and their use as muscarinic M3 receptor ligands |
Sep, 2020
(5 years ago) | |
| US7078412 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(5 years ago) | |
| US10588895 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(5 years ago) | |
| US6071498 | COVIS | Inhaler for powdered medicaments |
Jun, 2016
(9 years ago) | |
| US6681768 | COVIS | Powder formulation disintegrating system and method for dry powder inhalers |
Aug, 2022
(3 years ago) | |
| US10085974 | COVIS | Dosage and formulation |
Mar, 2029
(3 years from now) | |
| US11000517 | COVIS | Dosage and formulation |
Mar, 2029
(3 years from now) | |
| US8051851 | COVIS | Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler |
Apr, 2027
(1 year, 2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 23, 2017 |
| M(M-256) | Mar 29, 2022 |
Drugs and Companies using ACLIDINIUM BROMIDE ingredient
NCE-1 date: 23 July, 2016
Market Authorisation Date: 23 July, 2012
Treatment: Maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd); Maintenance treatment of chronic obstructive pulmonary disease (copd); Treatment of a respiratory di...
Dosage: POWDER, METERED
More Information on Dosage
TUDORZA PRESSAIR family patents
64. Utibron Neohaler patent expiration
UTIBRON NEOHALER's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6878721 | NOVARTIS | Beta2-adrenoceptor agonists |
Feb, 2025
(11 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8029768 | NOVARTIS | Treatment of respiratory diseases |
Apr, 2021
(4 years ago) | |
| US7820694 | NOVARTIS | Beta-2-adrenoreceptor agonists |
Jun, 2020
(5 years ago) | |
| US8658673 | NOVARTIS | BETA2-adrenoreceptor agonists |
Jun, 2020
(5 years ago) | |
| US6582678 | NOVARTIS | Carrier particles for use in dry powder inhalers |
Apr, 2018
(7 years ago) | |
| US6521260 | NOVARTIS | Carrier particles for use in dry powder inhalers |
Jan, 2016
(10 years ago) | |
| US8580306 | NOVARTIS | Particles for use in a pharmaceutical composition |
Jun, 2021
(4 years ago) | |
| US9962338 | NOVARTIS | Method of making particles for use in a pharmaceutical composition |
Jun, 2021
(4 years ago) | |
| US8796307 | NOVARTIS | Beta2-adrenoreceptor agonists |
Jun, 2020
(5 years ago) | |
| US8283362 | NOVARTIS | Beta-2-adrenoreceptor agonists |
Jun, 2020
(5 years ago) | |
| US7229607 | NOVARTIS | Treatment of respiratory disease |
Apr, 2021
(4 years ago) | |
| US7736670 | NOVARTIS | Method of making particles for use in a pharmaceutical composition |
Jun, 2021
(4 years ago) | |
| US8067437 | NOVARTIS | Beta-2-adrenoreceptor agonists |
Jun, 2020
(5 years ago) | |
| US8956661 | NOVARTIS | Method of making composite particles for use in pharmaceutical compositions and composite particles and compositions thereof |
Jun, 2021
(4 years ago) | |
| US8435567 | NOVARTIS | Pharmaceutical compositions of hydrophobic surface-modified active substance microparticles for inhalation |
Jun, 2021
(4 years ago) | |
| US8303991 | NOVARTIS | Method of making particles for use in a pharmaceutical composition |
Jun, 2021
(4 years ago) | |
| US8048451 | NOVARTIS | Pharmaceutical compositions for inhalation |
Jun, 2021
(4 years ago) | |
| US9931304 | NOVARTIS | Method of making particles for use in a pharmaceutical composition |
Jun, 2021
(4 years ago) | |
| US8182838 | NOVARTIS | Dry powder composition comprising co-jet milled particles for pulmonary inhalation |
Oct, 2028
(2 years from now) | |
| US8479730 | NOVARTIS | Inhaler device |
Oct, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 01, 2016 |
| New Product(NP) | Oct 29, 2018 |
Drugs and Companies using GLYCOPYRROLATE; INDACATEROL MALEATE ingredient
NCE-1 date: 02 July, 2015
Market Authorisation Date: 29 October, 2015
Treatment: Long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd)
Dosage: POWDER
More Information on Dosage
UTIBRON NEOHALER family patents
65. Vascepa patent expiration
VASCEPA's oppositions filed in EPO
VASCEPA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8188146 | AMARIN | Highly purified ethyl EPA and other EPA derivatives |
Jan, 2020
(6 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8188146 | AMARIN | Highly purified ethyl EPA and other EPA derivatives |
Jan, 2020
(6 years ago) | |
| US8377920 | AMARIN | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
| US8367652 | AMARIN | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
| US8399446 | AMARIN | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
| US8431560 | AMARIN | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
| US8501225 | AMARIN | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(4 years from now) | |
| US8617593 | AMARIN | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(4 years from now) | |
| US10278936 | AMARIN | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(7 years from now) | |
| US10555925 | AMARIN | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(7 years from now) | |
| US8618166 | AMARIN | Methods of treating mixed dyslipidemia |
Apr, 2030
(4 years from now) | |
| US8623406 | AMARIN | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(4 years from now) | |
| US8642077 | AMARIN | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(4 years from now) | |
| US8669245 | AMARIN | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
Jun, 2030
(4 years from now) | |
| US8680144 | AMARIN | Methods of treating mixed dyslipidemia |
Feb, 2030
(4 years from now) | |
| US8703185 | AMARIN | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(4 years from now) | |
| US8691871 | AMARIN | Methods of treating mixed dyslipidemia |
Apr, 2030
(4 years from now) | |
| US8709475 | AMARIN | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(4 years from now) | |
| US8293728 | AMARIN | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
| US8314086 | AMARIN | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
| US8318715 | AMARIN | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
| US8710041 | AMARIN | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy |
Jun, 2030
(4 years from now) | |
| US9693984 | AMARIN | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(7 years from now) | |
| US9623001 | AMARIN | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(7 years from now) | |
| US9693985 | AMARIN | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(7 years from now) | |
| US9693986 | AMARIN | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(7 years from now) | |
| US10010517 | AMARIN | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(4 years from now) | |
| US9918954 | AMARIN | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(7 years from now) | |
| US10278937 | AMARIN | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(7 years from now) | |
| US10383840 | AMARIN | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(7 years from now) | |
| US8357677 | AMARIN | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
| US10555924 | AMARIN | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(7 years from now) | |
| US9700537 | AMARIN | Composition for preventing the occurrence of cardiovascular event in multiple risk patient |
May, 2027
(1 year, 3 months from now) | |
| US9198892 | AMARIN | Composition and/or method for preventing onset and/or recurrence of cardiovascular events |
Sep, 2027
(1 year, 7 months from now) | |
| US8410086 | AMARIN | Compositions and methods for lowering triglycerides |
Jun, 2030
(4 years from now) | |
| US8454994 | AMARIN | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(4 years from now) | |
| US8455472 | AMARIN | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
Jun, 2030
(4 years from now) | |
| US9603826 | AMARIN | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(7 years from now) | |
| US8415335 | AMARIN | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
| US8524698 | AMARIN | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
| US11154526 | AMARIN | Methods of treating mixed dyslipidemia |
Apr, 2030
(4 years from now) | |
| US10568861 | AMARIN | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(7 years from now) | |
| US8551521 | AMARIN | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(4 years from now) | |
| US8617594 | AMARIN | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(4 years from now) | |
| US8293727 | AMARIN | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
| US8563608 | AMARIN | Methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
Apr, 2030
(4 years from now) | |
| US8445003 | AMARIN | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(4 years from now) | |
| US10668042 | AMARIN | Methods of reducing the risk of cardiovascular events in a subject |
Jun, 2033
(7 years from now) | |
| US10576054 | AMARIN | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(7 years from now) | |
| US11717504 | AMARIN | Methods of reducing the risk of cardiovascular events in a subject |
Apr, 2030
(4 years from now) | |
| US10792270 | AMARIN | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(7 years from now) | |
| US10786478 | AMARIN | Methods of reducing the risk of cardiovascular events in a subject |
Jun, 2033
(7 years from now) | |
| US10792267 | AMARIN | Methods of treating mixed dyslipidemia |
Apr, 2030
(4 years from now) | |
| US10842768 | AMARIN | Compositions and methods for lowering triglycerides |
Jun, 2030
(4 years from now) | |
| US10842766 | AMARIN | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(4 years from now) | |
| US10881632 | AMARIN | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(4 years from now) | |
| US10894028 | AMARIN | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(7 years from now) | |
| US8546372 | AMARIN | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
| US8445013 | AMARIN | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(4 years from now) | |
| US8518929 | AMARIN | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
| US8426399 | AMARIN | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
| US11213504 | AMARIN | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(4 years from now) | |
| US12171738 | AMARIN | Compositions and methods for lowering triglycerides |
Feb, 2030
(4 years from now) | |
| US9610272 | AMARIN | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(7 years from now) | |
| US10278935 | AMARIN | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(7 years from now) | |
| US10265287 | AMARIN | Methods of reducing triglycerides and LDL-C |
Apr, 2030
(4 years from now) | |
| US11369582 | AMARIN | Methods of reducing the risk of cardiovascular events in a subject |
Jun, 2033
(7 years from now) | |
| US11298333 | AMARIN | Methods of reducing the risk of cardiovascular events in a subject |
Jun, 2033
(7 years from now) | |
| US8298554 | AMARIN | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(4 years from now) | |
| US11103477 | AMARIN | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(4 years from now) | |
| US11116742 | AMARIN | Methods of reducing the risk of cardiovascular events in a subject |
Jun, 2033
(7 years from now) | |
| US11000499 | AMARIN | Methods of reducing the risk of cardiovascular events in a subject |
Jun, 2033
(7 years from now) | |
| US8440650 | AMARIN | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 26, 2015 |
| New Chemical Entity Exclusivity(NCE) | Jul 26, 2017 |
| New Indication(I-819) | Dec 13, 2022 |
Drugs and Companies using ICOSAPENT ETHYL ingredient
NCE-1 date: 26 July, 2016
Market Authorisation Date: 16 February, 2017
Treatment: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia; Use of vascepa to treat hypertriglyceridemia in an adult patient with elevated triglyceride (tg) levels (>= 150 mg/d...
Dosage: CAPSULE
How can I launch a generic of VASCEPA before it's drug patent expiration?
More Information on Dosage
VASCEPA family patents
66. Venlafaxine Besylate patent expiration
VENLAFAXINE BESYLATE IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6717015 | ALMATICA | Venlafaxine besylate |
Mar, 2023
(2 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7776358 | ALMATICA | Extended release venlafaxine besylate tablets |
May, 2028
(2 years from now) | |
Drugs and Companies using VENLAFAXINE BESYLATE ingredient
Market Authorisation Date: 29 June, 2022
Treatment: Treatment of depression and generalized anxiety disorder
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
VENLAFAXINE BESYLATE family patents
67. Veramyst patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8752543 | GLAXOSMITHKLINE | Fluid dispensing device |
Apr, 2026
(a month from now) | |
| US6858596 | GLAXOSMITHKLINE | Formulation containing anti-inflammatory androstane derivative |
Aug, 2021
(4 years ago) | |
| US7101866 | GLAXOSMITHKLINE | Anti-inflammatory androstane derivative |
Aug, 2021
(4 years ago) | |
| US7541350 | GLAXOSMITHKLINE | Formulation containing anti-inflammatory androstane derivative |
Aug, 2021
(4 years ago) | |
| US8062264 | GLAXOSMITHKLINE | Fluid dispensing device |
Apr, 2026
(a month from now) | |
| US9320862 | GLAXOSMITHKLINE | Fluid dispensing device |
Nov, 2024
(1 year, 3 months ago) | |
| US8147461 | GLAXOSMITHKLINE | Fluid dispensing device |
Mar, 2025
(10 months ago) | |
| US8347879 | GLAXOSMITHKLINE | Fluid dispensing device |
Apr, 2027
(1 year, 1 month from now) | |
Drugs and Companies using FLUTICASONE FUROATE ingredient
Market Authorisation Date: 27 April, 2007
Treatment: The treatment of the symptoms of seasonal and perennial allergic rhinitis in patients 2 years of age and older; Treatment of rhinitis comprising the nasal application of a pharmaceutical formulation a...
Dosage: SPRAY, METERED
More Information on Dosage
VERAMYST family patents
68. Vyleesi (autoinjector) patent expiration
VYLEESI (AUTOINJECTOR)'s oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6579968 | COSETTE | Compositions and methods for treatment of sexual dysfunction |
Jun, 2021
(4 years ago) | |
| US6794489 | COSETTE | Compositions and methods for treatment of sexual dysfunction |
Jun, 2025
(7 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9352013 | COSETTE | Uses of bremelanotide in therapy for female sexual dysfunction |
Nov, 2033
(7 years from now) | |
| US11590209 | COSETTE | Use of bremelanotide in patients with controlled hypertension |
Apr, 2041
(15 years from now) | |
| US9700592 | COSETTE | Uses of bremelanotide in therapy for female sexual dysfunction |
Nov, 2033
(7 years from now) | |
| US10286034 | COSETTE | Uses of bremelanotide in therapy for female sexual dysfunction |
Nov, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 21, 2024 |
Drugs and Companies using BREMELANOTIDE ACETATE ingredient
NCE-1 date: 22 June, 2023
Market Authorisation Date: 21 June, 2019
Treatment: Treatment of hypoactive sexual desire disorder (hsdd); Treating acquired, generalized hypoactive sexual desire disorder (hsdd) in a premenopausal female patient with controlled hypertension by injecti...
Dosage: SOLUTION
More Information on Dosage
VYLEESI (AUTOINJECTOR) family patents
69. Vyondys 53 patent expiration
VYONDYS 53's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9416361 | SAREPTA | Splice-region antisense composition and method |
May, 2021
(4 years ago) | |
| US10227590 | SAREPTA | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(7 months ago) | |
| US10968450 | SAREPTA | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(7 months ago) | |
| US9024007 | SAREPTA | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(7 months ago) | |
| US10421966 | SAREPTA | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(7 months ago) | |
| US9994851 | SAREPTA | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(7 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10533174 | SAREPTA | Splice-region antisense composition and method |
May, 2021
(4 years ago) | |
| US10266827 | SAREPTA | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(7 months ago) | |
| USRE47691 | SAREPTA | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2028
(2 years from now) | |
| US10995337 | SAREPTA | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(7 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 12, 2024 |
| Orphan Drug Exclusivity(ODE-280) | Dec 12, 2026 |
Drugs and Companies using GOLODIRSEN ingredient
NCE-1 date: 13 December, 2023
Market Authorisation Date: 12 December, 2019
Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients having a confirmed mutation of the dmd gene that is amenable to exon 53 skipping
Dosage: SOLUTION
More Information on Dosage
VYONDYS 53 family patents
70. Vyvanse patent expiration
VYVANSE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7662787 | TAKEDA | Abuse resistant lysine amphetamine compounds |
Feb, 2023
(2 years ago) | |
| US7659253 | TAKEDA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(2 years ago) | |
| US7655630 | TAKEDA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(2 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7671030 | TAKEDA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(2 years ago) | |
| US7659254 | TAKEDA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(2 years ago) | |
|
US7662788 (Pediatric) | TAKEDA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 years ago) | |
| US7713936 | TAKEDA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(2 years ago) | |
|
US7700561 (Pediatric) | TAKEDA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 years ago) | |
|
US7723305 (Pediatric) | TAKEDA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 years ago) | |
| US7659253 | TAKEDA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(2 years ago) | |
| US7687467 | TAKEDA | Abuse-resistant amphetamine prodrugs |
Apr, 2023
(2 years ago) | |
| US7723305 | TAKEDA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(2 years ago) | |
| US7718619 | TAKEDA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(2 years ago) | |
| US7671031 | TAKEDA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(2 years ago) | |
| US7662788 | TAKEDA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(2 years ago) | |
| US7678770 | TAKEDA | Abuse-resistant amphetamine prodrugs |
Mar, 2023
(2 years ago) | |
| US7105486 | TAKEDA | Abuse-resistant amphetamine compounds |
Jun, 2023
(2 years ago) | |
| US7678771 | TAKEDA | Abuse-resistant amphetamine prodrugs |
Mar, 2023
(2 years ago) | |
| US7674774 | TAKEDA | Abuse-resistant amphetamine prodrugs |
Mar, 2023
(2 years ago) | |
| US7655630 | TAKEDA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(2 years ago) | |
|
US7671030 (Pediatric) | TAKEDA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 years ago) | |
|
US7718619 (Pediatric) | TAKEDA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 years ago) | |
| US7700561 | TAKEDA | Abuse-resistant amphetamine prodrugs |
Jun, 2023
(2 years ago) | |
| US7687466 | TAKEDA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(2 years ago) | |
| US7662787 | TAKEDA | Abuse resistant lysine amphetamine compounds |
Feb, 2023
(2 years ago) | |
| US7223735 | TAKEDA | Abuse resistant lysine amphetamine compounds |
Jun, 2023
(2 years ago) | |
|
US7662787 (Pediatric) | TAKEDA | Abuse resistant lysine amphetamine compounds |
Aug, 2023
(2 years ago) | |
|
US7671031 (Pediatric) | TAKEDA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 years ago) | |
|
US7674774 (Pediatric) | TAKEDA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 years ago) | |
|
US7713936 (Pediatric) | TAKEDA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 years ago) | |
|
US7105486 (Pediatric) | TAKEDA | Abuse-resistant amphetamine compounds |
Aug, 2023
(2 years ago) | |
|
US7223735 (Pediatric) | TAKEDA | Abuse resistant lysine amphetamine compounds |
Aug, 2023
(2 years ago) | |
|
US7655630 (Pediatric) | TAKEDA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 years ago) | |
|
US7659253 (Pediatric) | TAKEDA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 years ago) | |
|
US7659254 (Pediatric) | TAKEDA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 years ago) | |
|
US7678770 (Pediatric) | TAKEDA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 years ago) | |
|
US7678771 (Pediatric) | TAKEDA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 years ago) | |
|
US7687466 (Pediatric) | TAKEDA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 years ago) | |
|
US7687467 (Pediatric) | TAKEDA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 23, 2012 |
| M(M-82) | Apr 05, 2013 |
| New Patient Population(NPP) | Nov 10, 2013 |
| New Indication(I-645) | Jan 31, 2015 |
| New Indication(I-703) | Jan 30, 2018 |
| M(M-188) | Oct 14, 2019 |
Drugs and Companies using LISDEXAMFETAMINE DIMESYLATE ingredient
Market Authorisation Date: 28 January, 2017
Treatment: For the treatment of attention deficit hyperactivity disorder (adhd); Treatment of attention deficit hyperactivity disorder (adhd) in adults; Indicated for the treatment of attention-deficit/hyperacti...
Dosage: CAPSULE
How can I launch a generic of VYVANSE before it's drug patent expiration?
More Information on Dosage
VYVANSE family patents
71. Xarelto patent expiration
XARELTO's oppositions filed in EPO
XARELTO IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7585860 | JANSSEN | Substituted oxazolidinones and their use in the field of blood coagulation |
Dec, 2020
(5 years ago) | |
| US7157456 | JANSSEN | Substituted oxazolidinones and their use in the field of blood coagulation |
Aug, 2024
(1 year, 5 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7585860 | JANSSEN | Substituted oxazolidinones and their use in the field of blood coagulation |
Dec, 2020
(5 years ago) | |
| US7592339 | JANSSEN | Substituted oxazolidinones and their use in the field of blood coagulation |
Dec, 2020
(5 years ago) | |
| US9415053 | JANSSEN | Solid, orally administrable pharmaceutical composition |
Nov, 2024
(1 year, 2 months ago) | |
| US9539218 | JANSSEN | Prevention and treatment of thromboembolic disorders |
Feb, 2034
(8 years from now) | |
| US10828310 | JANSSEN | Reducing the risk of cardiovascular events |
Jan, 2039
(12 years from now) | |
|
US7157456 (Pediatric) | JANSSEN | Substituted oxazolidinones and their use in the field of blood coagulation |
Feb, 2025
(11 months ago) | |
|
US9415053 (Pediatric) | JANSSEN | Solid, orally administrable pharmaceutical composition |
May, 2025
(8 months ago) | |
|
US9539218 (Pediatric) | JANSSEN | Prevention and treatment of thromboembolic disorders |
Aug, 2034
(8 years from now) | |
|
US10828310 (Pediatric) | JANSSEN | Reducing the risk of cardiovascular events |
Jul, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-643) | Nov 04, 2014 |
| New Indication(I-660) | Nov 02, 2015 |
| New Indication(I-661) | Nov 02, 2015 |
| New Indication(I-662) | Nov 02, 2015 |
| New Chemical Entity Exclusivity(NCE) | Jul 01, 2016 |
| New Dosing Schedule(D-168) | Oct 27, 2020 |
| New Indication(I-824) | Oct 11, 2021 |
| New Indication(I-810) | Oct 11, 2022 |
| M(M-284) | Mar 10, 2023 |
| New Indication(I-867) | Aug 23, 2024 |
| New Product(NP) | Dec 20, 2024 |
| Pediatric Exclusivity(PED) | Jun 20, 2025 |
Drugs and Companies using RIVAROXABAN ingredient
NCE-1 date: 24 February, 2024
Market Authorisation Date: 11 October, 2018
Treatment: Reduction in the risk of recurrence of deep vein thrombosis (dvt) and pulmonary embolism; Prophylaxis of deep vein thrombosis (dvt); Treatment of venous thromboembolism (vte) and the reduction in the ...
Dosage: TABLET; FOR SUSPENSION
How can I launch a generic of XARELTO before it's drug patent expiration?
More Information on Dosage
XARELTO family patents
72. Xeglyze patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9839631 | HATCHTECH | Methods and compositions for controlling ectoparasites |
Jul, 2024
(1 year, 6 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8212038 | HATCHTECH | Methods and compositions for controlling ectoparasites |
Jul, 2024
(1 year, 6 months ago) | |
| US10292389 | HATCHTECH | Pediculicidal composition |
Dec, 2034
(8 years from now) | |
| US9357783 | HATCHTECH | Methods and compositions for controlling ectoparasites |
Jul, 2024
(1 year, 6 months ago) | |
| US7812163 | HATCHTECH | Methods and compositions for controlling ectoparasites |
Oct, 2026
(8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 24, 2025 |
Drugs and Companies using ABAMETAPIR ingredient
NCE-1 date: 24 July, 2024
Market Authorisation Date: 24 July, 2020
Treatment: Topical treatment of head lice infestation in patients 6 months of age and older
Dosage: LOTION
More Information on Dosage
XEGLYZE family patents
73. Xeljanz patent expiration
XELJANZ's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7301023 | PF PRISM CV | Chiral salt resolution |
Dec, 2020
(5 years ago) | |
| US7265221 | PF PRISM CV | Pyrrolo[2,3-d]pyrimidine compounds |
Dec, 2020
(5 years ago) | |
| US6965027 | PF PRISM CV | Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate |
Mar, 2023
(2 years ago) | |
| USRE41783 | PF PRISM CV | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2025
(2 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7842699 | PF PRISM CV | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2020
(5 years ago) | |
| US6956041 | PF PRISM CV | Pyrrolo[2,3-d]pyrimidine compounds |
Dec, 2020
(5 years ago) | |
| US7301023 | PF PRISM CV | Chiral salt resolution |
May, 2022
(3 years ago) | |
| US6965027 | PF PRISM CV | Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate |
Mar, 2023
(2 years ago) | |
| US7091208 | PF PRISM CV | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2020
(5 years ago) | |
| US7265221 | PF PRISM CV | Pyrrolo[2,3-d]pyrimidine compounds |
Dec, 2020
(5 years ago) | |
|
USRE41783 (Pediatric) | PF PRISM CV | Pyrrolo[2,3-D]pyrimidine compounds |
Jun, 2026
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-135) | Feb 21, 2017 |
| New Chemical Entity Exclusivity(NCE) | Nov 06, 2017 |
| New Indication(I-761) | Dec 14, 2020 |
| New Indication(I-780) | May 30, 2021 |
| New Product(NP) | Sep 25, 2023 |
| New Patient Population(NPP) | Sep 25, 2023 |
| New Indication(I-879) | Dec 14, 2024 |
| M(M-14) | Feb 21, 2028 |
| Pediatric Exclusivity(PED) | Aug 21, 2028 |
Drugs and Companies using TOFACITINIB CITRATE ingredient
NCE-1 date: 22 August, 2027
Market Authorisation Date: 06 November, 2012
Treatment: Treatment of adult patients with moderately to severely active ulcerative colitis (uc); Treatment of rheumatoid arthritis
Dosage: TABLET
How can I launch a generic of XELJANZ before it's drug patent expiration?
More Information on Dosage
XELJANZ family patents
74. Xeljanz patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE41783 | PFIZER | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2025
(2 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
USRE41783 (Pediatric) | PFIZER | Pyrrolo[2,3-D]pyrimidine compounds |
Jun, 2026
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-135) | Feb 21, 2017 |
| New Chemical Entity Exclusivity(NCE) | Nov 06, 2017 |
| New Indication(I-761) | Dec 14, 2020 |
| New Indication(I-780) | May 30, 2021 |
| New Product(NP) | Sep 25, 2023 |
| New Patient Population(NPP) | Sep 25, 2023 |
| New Indication(I-879) | Dec 14, 2024 |
| M(M-14) | Feb 21, 2028 |
| Pediatric Exclusivity(PED) | Aug 21, 2028 |
Drugs and Companies using TOFACITINIB CITRATE ingredient
Market Authorisation Date: 25 September, 2020
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of XELJANZ before it's drug patent expiration?
More Information on Dosage
XELJANZ family patents
75. Xeljanz Xr patent expiration
XELJANZ XR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7301023 | PFIZER | Chiral salt resolution |
Dec, 2020
(5 years ago) | |
| US7265221 | PFIZER | Pyrrolo[2,3-d]pyrimidine compounds |
Dec, 2020
(5 years ago) | |
| US6956027 | PFIZER | N-terminally chemically modified protein compositions and methods |
Mar, 2023
(2 years ago) | |
| US6965027 | PFIZER | Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate |
Mar, 2023
(2 years ago) | |
| USRE41783 | PFIZER | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2025
(2 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7842699 | PFIZER | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2020
(5 years ago) | |
| US7091208 | PFIZER | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2020
(5 years ago) | |
| US6956041 | PFIZER | Pyrrolo[2,3-d]pyrimidine compounds |
Dec, 2020
(5 years ago) | |
| US11253523 | PFIZER | Tofacitinib oral sustained release dosage forms |
Mar, 2034
(8 years from now) | |
| US9937181 | PFIZER | Tofacitinib oral sustained release dosage forms |
Mar, 2034
(8 years from now) | |
| US10639309 | PFIZER | Tofacitinib oral sustained release dosage forms |
Mar, 2034
(8 years from now) | |
|
USRE41783 (Pediatric) | PFIZER | Pyrrolo[2,3-D]pyrimidine compounds |
Jun, 2026
(3 months from now) | |
|
US9937181 (Pediatric) | PFIZER | Tofacitinib oral sustained release dosage forms |
Sep, 2034
(8 years from now) | |
|
US10639309 (Pediatric) | PFIZER | Tofacitinib oral sustained release dosage forms |
Sep, 2034
(8 years from now) | |
|
US11253523 (Pediatric) | PFIZER | Tofacitinib oral sustained release dosage forms |
Sep, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 06, 2017 |
| New Indication(I-761) | Dec 14, 2020 |
| New Indication(I-879) | Dec 14, 2024 |
Drugs and Companies using TOFACITINIB CITRATE ingredient
NCE-1 date: 06 November, 2016
Market Authorisation Date: 23 February, 2016
Treatment: Treatment of adult patients with moderately to severely active ulcerative colitis (uc); Treatment of rheumatoid arthritis; A method of treating ulcerative colitis, by administering the formulation of ...
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of XELJANZ XR before it's drug patent expiration?
More Information on Dosage
XELJANZ XR family patents
76. Xepi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6335447 | FERRER INTERNACIONAL | Quinolonecarboxylic acid derivatives or salts thereof |
Nov, 2023
(2 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9180200 | FERRER INTERNACIONAL | Pharmaceutical topical compositions |
Jan, 2032
(5 years from now) | |
| US9399014 | FERRER INTERNACIONAL | Pharmaceutical topical compositions |
Dec, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 11, 2022 |
Drugs and Companies using OZENOXACIN ingredient
NCE-1 date: 11 December, 2021
Market Authorisation Date: 11 December, 2017
Treatment: Treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes
Dosage: CREAM
More Information on Dosage
XEPI family patents
77. Xtoro patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6432948 | FONSECA BIOSCIENCES | Use of 7-(2-oxa-5,8-diazabicylco[4.3.0]non-8-yl)-quinolone carboxylic acid and naphthyridon carboxylic acid derivatives for the treatment of heliobacter pylori infections and associated gastroduodenal diseases |
Apr, 2017
(8 years ago) | |
| US6133260 | FONSECA BIOSCIENCES | Use of 7-(2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-quinolone carboxylic acid and naphthyridon carboxylic acid derivatives for the treatment of Helicobacter pylori infections and associated gastroduodenal diseases |
Apr, 2017
(8 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8536167 | FONSECA BIOSCIENCES | Methods for treating ophthalmic, otic, or nasal infections |
Aug, 2031
(5 years from now) | |
| US9504691 | FONSECA BIOSCIENCES | Finafloxacin suspension compositions |
Nov, 2033
(7 years from now) | |
| US9119859 | FONSECA BIOSCIENCES | Methods for treating otic infections |
Jul, 2030
(4 years from now) | |
| US9993483 | FONSECA BIOSCIENCES | Compositions and methods for treating ophthalmic, octic, or nasal infections |
Jul, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 17, 2019 |
| Pediatric Exclusivity(PED) | Jun 17, 2020 |
Drugs and Companies using FINAFLOXACIN ingredient
NCE-1 date: 18 June, 2019
Market Authorisation Date: 17 December, 2014
Treatment: Treatment of acute otitis externa
Dosage: SUSPENSION/DROPS
More Information on Dosage
XTORO family patents
78. Zontivity patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7235567 | KEY | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist |
Jun, 2021
(4 years ago) | |
| US7304078 | KEY | Thrombin receptor antagonists |
Dec, 2027
(1 year, 10 months from now) | |
| US7713999 | KEY | Thrombin receptor antagonists |
May, 2024
(1 year, 8 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 08, 2019 |
Drugs and Companies using VORAPAXAR SULFATE ingredient
NCE-1 date: 08 May, 2018
Market Authorisation Date: 08 May, 2014
Treatment: Reduction of thrombotic cardiovascular events; Reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (mi) or with peripheral arterial disease (pad)
Dosage: TABLET
More Information on Dosage
ZONTIVITY family patents
79. Zyvox patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6559305 | PFIZER | Linezolid—crystal form II |
Jan, 2021
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6559305 | PFIZER | Linezolid—crystal form II |
Jan, 2021
(5 years ago) | |
|
US6559305 (Pediatric) | PFIZER | Linezolid—crystal form II |
Jul, 2021
(4 years ago) | |
| US5688792 | PFIZER | Substituted oxazine and thiazine oxazolidinone antimicrobials |
Nov, 2014
(11 years ago) | |
|
US5688792 (Pediatric) | PFIZER | Substituted oxazine and thiazine oxazolidinone antimicrobials |
May, 2015
(10 years ago) | |
Drugs and Companies using LINEZOLID ingredient
Market Authorisation Date: 18 April, 2000
Treatment: Treatment of microbial infections
Dosage: SOLUTION
How can I launch a generic of ZYVOX before it's drug patent expiration?
More Information on Dosage
ZYVOX family patents